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Die CD44 Expression auf hämatopoetischen Stammzellen (HSC) ist essentiell 
für das Homing in die osteogene Nische und die Aufrechterhaltung der 
Quieszenz. Es ist nicht bekannt, welche CD44-Isoform, die CD44-Standardform 
oder varianten Isoformen (CD44s und CD44v), nötig ist. Ebenso wurde die 
mögliche Rolle des auf Stromazellen exprimierten CD44 bis jetzt nicht 
untersucht. 
Eine Analyse der CD44 Expression auf HSC und Stromazellen, die aus 
langzeit-kultiviertem Knochenmark generiert wurden (Long Term Bone Marrow 
Culture-stroma cells; LTBMC-stroma cells) zeigte eine dominante CD44s 
Expression in CD117+SCA1+ HSC, während CD44v6, CD44v7 und CD44v10 
niedrig exprimiert waren. Die LTBMC-Stromazellen zeigten überwiegend 
CD44v7 Expression. 
Des weiteren wurden Adhäsionsmoleküle wie CD49d und CD54, einige 
wichtige Vorläufermarker wie CD16, CD24 und Cytokinrezeptoren wie CD184 
(SDF-1 Rezeptor) ebenfalls auf HSC und LTBMC-Stroma gefunden. Die CD44-
Moleküle auf HSC und LTBMC-Stroma zeigen distinkte Komplexbildungen. In 
beiden Zellpopulationen co-immunoprezipitiert CD44 mit CD49d und CD54, 
während CD44v7 im LTBMC-Stroma ausschließlich mit CD49d assoziiert. 
Funktionelle Studien deuten daraufhin, dass die Interaktion des CD44-CD49d-
Komplexes auf HSC mit der Nische für deren Quieszenz verantwortlich ist. Des 
Weiteren spielt CD44 auf HSC durch eine erhöhte Expression anti-
apoptotischer Proteine eine wichtige Rolle bei der Apoptoseresistenz. Diese 
Funktionen sind durch die koordinierte Interaktion beider Zellpopulationen 
möglich. 
Da HSC und LTBMC-Stroma über CD44 interagieren, kann CD44 
möglicherweise auch die Interaktion von HSC versus leukämische Zellen (LSC) 
mit der osteogen Nische gezielt beeinflussen. Tatsächlich wird durch die 
Blockade von CD44 nicht nur das Homing der hämatopoetischen Stammzellen 
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und der leukämischen Zellen verhindert, sondern es wurde beschrieben, dass 
in leukämischen Zellen Differenzierung und Apoptose ausgelöst wird.  
Eine Analyse der CD44-Blockade auf das Wachstum der T-Lymphomazelllinie 
EL4 zeigte ein verlangsamtes Wachstum in vivo und erhöhte Apoptose der 
leukämischen Zellen. In mit Knochenmarkszellen rekonstituierten Mäusen 
induzieren anti-CD44-Antikörper Apoptose in T-Vorläuferzellen stärker als in 
Tumorzellen, so dass die Überlebenszeit der Mäuse verkürzt und die 
Metastasierung erhöht ist. 
In vitro, führt die CD44-Blockade zu einer 2-4-fach erhöhten Apoptoserate in 
EL4-Zellen. Die Expression der Todesrezeptoren CD95, TRAIL, und TNFRI 
und auch die durch CD95-Aktivierung ausgelöste Apoptose bleibt unverändert: 
Anstatt dessen wird die Apoptose durch eine Depolarisierung der 
Mitochondrien ausgelöst, welche mit der Spaltung der Caspase-9 einhergeht 
und durch einen Caspase-9-Inhibitor gehemmt wird. Die Apoptose wird durch 
die Aktivierung der CD44-assoziierten Phosphatase 2A (PP2A) initiiert und 
über ERK1/2-Dephosphorylierung weitergeleitet, ohne ERK1/ 2 abzubauen. 
Das bedeutet, dass anti-CD44-Antikörper leukämische T-Zellen über den 












1. Stem cells and Hematopoietic stem cells: 
It has long been known that stem cells are capable of renewing themselves and 
that they can generate multiple cell types. Efforts are now underway to harness 
stem cells and to take advantage of this new found capability, with the goal of 
devising new and more effective treatments for a host of diseases and 
disabilities. The stem cells that form blood and immune cells are known as 
hematopoietic stem cells (HSC). They are ultimately responsible for the 
constant renewal of bloodthe production of billions of new blood cells each 
day. 
1.1 Definition of stem cells: 
A stem cell is an unspecialized cell that is capable of replicating or self 
renewing itself and developing into specialized cells of a variety of cell types. 
The product of a stem cell undergoing division is at least one additional stem 
cell that has the same capabilities of the originating cell. 
The critical balance between stem and differentiated cell populations is crucial 
for the long term maintenance of functional tissue types. Stem cells maintain 
this balance by choosing one of several alternate fates: self-renewal, 
commitment to differentiate, and senescence or cell death. These 
characteristics comprise the core criteria by which these cells are usually 
defined. The self-renewal property is important, as it allows for extended 
production of the corresponding differentiated cells throughout the life span [1, 
2]. 
The best example of a stem cell is the bone marrow stem cell that is 
unspecialized and able to specialize into blood cells, such as white blood cells 
and red blood cells, and these new cell types have special functions, such as 
being able to produce antibodies, act as scavengers to combat infection and 
transport gases. Basically, a stem cell remains uncommitted until it receives a 
signal to develop into a specialized cell. Stem cells serve as a repair system by 
being able to divide without limit to replenish other cells.  
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Today, stem cells have been isolated from preimplantation embryos, fetuses, 
adults and the umbilical cord and under certain conditions, these 
undifferentiated stem cells can be pluripotent (ability to give rise to cells from all 
three germ layers, viz. ectoderm, mesoderm and endoderm) or multipotent 













1.2 Hematopoitic stem cells and Hematopoiesis 
1.2.1 Hematopoitic stem cells: 
A hematopoietic stem cell is a cell isolated from the blood or bone marrow that 
can renew itself, can mobilize out of the bone marrow into circulating blood, and 
can undergo programmed cell death, called apoptosisa process by which 




Scheme 2:  Hematopoietic and stromal cell differentiation. (stem cell 
information at stemcells.nih.gov ) 
All of the mature blood cells in the body are generated from a relatively small 
number of hematopoietic stem cells (HSC) and progenitors [3, 4]. Murine 
models, particularly short- and long-term transplant studies, have provided a 
number of insights into the biology of HSC and progenitors [5, 6]. The results of 
these studies have demonstrated that HSC are able to generate every lineage 
found in the hematopoietic system including red blood cells, platelets, and a 
variety of lymphoid and myeloid cells [3-6]. Some of the most important 
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lymphoid cells include natural killer (NK) cells,T cells, and B cells, while 
important myeloid cells include granulocytes, monocytes, macrophages, 
microglial cells, and dendritic cells [7]. Each of these cell types can be 
generated from a single HSC, and each HSC has an enormous capacity to 
generate large numbers of these cells over many years and perhaps even 
decades. In the mouse, a single HSC can reconstitute the entire hematopoietic 
system for the natural lifespan of the animal [8]. HSC are detected in the bone 
marrow at a frequency between 1: 107 - 108 [9]. While HSC are primarily found 
in the bone marrow, they are present in a variety of other tissues including 
peripheral blood and umbilical cord blood, and are found at low numbers in the 
liver, spleen, and perhaps many organs [10]. These HSC may have somewhat 
different properties, but they all have the ability to generate all the different 
blood lineages in large numbers for a prolonged period of time.  
Downstream of the common lymphoid progenitors (CLPs) and common myeloid 
progenitors (CMPs) are more mature progenitors that are further restricted in 
the number and type of lineages that they can generate [11, 12]. When a bone 
marrow or blood stem cell transplant is performed, it appears that progenitors 
contribute to engraftment for only a short period of time, while long-term blood 













The process of hematopoiesis involves a complex interplay between the 
intrinsic genetic processes of blood cells and their environment. This interplay 
determines whether HSC, progenitors, and mature blood cells remain 
quiescent, proliferate, differentiate, self-renew, or undergo apoptosis.[14-16] All 
of the genetic and environmental mechanisms that govern blood production 
operate by affecting the relative balance of these fundamental cellular 
processes. Under normal conditions, the majority of HSC and many progenitors 
are quiescent in the G0 phase of the cell cycle; however, many of the more 
mature progenitors are proliferating and producing mature offspring [17]. In the 
absence of any stresses, this is balanced by the rate of apoptosis in progenitors 
and mature cells [15]. In the event of a stress such as bleeding or infection, 
several processes occur. Stored pools of cells in the marrow or adherent to the 
endothelium are quickly released into the circulation in order to localize to the 
site of injury [18]. Fewer progenitors and mature cells undergo apoptosis [19, 
20]. In addition, quiescent progenitors and HSC are stimulated by a variety of 
growth factors to proliferate and differentiate into mature white cells, red blood 
cells, and platelets. When the bleeding, infection, or other underlying stress 
ceases and the demand for blood cells returns to normal, the antiapoptotic and 
proliferative processes wind down, blood cells are redistributed back to their 
storage sites, and the kinetics of hematopoiesis return to baseline levels. This 
process repeats itself innumerable times during the lifespan of an individual and 
is seen in an exaggerated form following chemotherapy or bone marrow 
transplantation. 
Probably the best characterized environmental regulators of hematopoiesis are 
cellular microenvironment, known as niche. It functions as an extrinsic 
regulatory system, which maintains and governs the location, adhesiveness, 
retention, homing, mobilization, quiescence/activation, symmetric/asymmetric 
division and differentiation. [21]  
Cytokines are a broad family of proteins that mediate positive and negative 
affects on cellular quiescence, apoptosis, proliferation, and differentiation. In 
general, cytokines function by engaging a specific receptor and activating a 
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variety of signaling pathways. This includes activation of tyrosine kinases such 
as focal adhesion kinase, pp60src, and c-Abl, MAP kinases, jun Kinase (JNK), 
and protein kinase C (PKC) [22]. Mediators of cell growth and differentiation 
such as c-src, phosphoinositides, protein kinase C, and growth factor-mediated 
signaling pathways are also modulated by cytokines. Cytokines including 
interleukin-3 and GM-CSF induce cell proliferation, while other cytokines 
including flt-3 ligand and kit ligand protect cells from apoptosis and sensitize 
them to the effects of growth promoting cytokines [23-25]. Cytokines may also 
facilitate the interactions between stem cells and elements in the 
microenvironment including extracellular matrix (ECM) components [26]. 
Regulators of HSC including transforming growth factor-beta (TGF-く) and 
tumor necrosis factor-alpha (TNF-g) modulate cell cycle activity and 
engraftment [27]. Some cytokines including Wnt and the notch ligand family 
may also have important effects on stem cell biology [28, 29]. Some cytokines, 
including TNF-g, may be either inhibitory or activating depending on their 
concentration and other ongoing physiologic processes [30]. Several known 
cytokines, such as kit ligand, exist in either a soluble or membrane-bound form 
and have different activities depending on whether they are bound or soluble 
and on the environmental context in which they are acting [25]. Hematopoietic 
regulatory cytokines are produced through both autocrine and paracrine 
mechanisms and in many cases are produced by non-hematopoietic cells 
including bone marrow stroma and endothelium. 
Chemokines are another class of compounds that are important regulators of 
hematopoiesis [31-33]. These molecules regulate blood cell trafficking and 
homing to sites of need and may also be negative and positive growth 
regulators [34]. Chemokines are composed of a large family of proteins that 
mediate a variety of processes including inflammation, leukocyte migration and 
development, angiogenesis, and tumor cell growth and metastasis. 
Chemokines bind to one or more of a large family of structurally related guanine 
protein-coupled transmembrane receptors. In hematopoiesis, chemokines 
inhibit progenitor growth, regulate migration of hematopoietic progenitors. For 
example, the chemokine SDF-1 (which binds the receptor CCXR4) is essential 
for trafficking of hematopoietic cells in the developing embryo, mediating 
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homing of HSC and progenitors to the bone marrow following transplantation 
and, in stem cell mobilization, for collecting peripheral blood stem cells for 
transplant purposes [31]. A number of other chemokines likely play important 
roles in hematopoiesis and are under active investigation. 
HSC and progenitors bind tightly to a number of ECM components including 
heparin sulfates, chemokines, collagens, laminin, thrombospondin-1, 
fibronectin, and others. These molecules provide a scaffold for colocalizing 
progenitors and HSC with a wide array of positive and negative cytokines and 
other growth regulators. In addition, ECM and stromal components may directly 
mediate signaling to HSC to activate growth, protect cells from apoptosis, or 
modulate responses to positive and negative regulatory factors. The adhesion 
molecules on HSC and progenitors that mediate binding to these ECM 
components include CD44, integrins, selectins, and mucins. Adherence of cells 
to microenvironmental elements can trigger a variety of signaling pathways and 
can lead to changes in intracellular ions such as proton (pH), calcium, and the 
small GTPase Rho as well as lipid mediators such as phosphoinositides, 
diacylglycerol, and arachidonic acid metabolites [35]. Adhesion may also 
regulate expression of immediate-early genes such as c-fos and key cell cycle 
events such as kinase activity of cyclin-cdk complexes and phosphorylation of 
the retinoblastoma (Rb) protein [36]. Cell adhesion may potentiate the 
responses to growth factors and by modulating the downstream components of 
growth factor signaling cascades including PI-3 kinase, AKT, and p70rsk [37]. 
Hematopoietic and non-hematopoietic cells that may regulate hematopoiesis 
include NK cells, T cells, macrophages, fibroblasts, osteoblasts, adipocytes, 
and perhaps even neurons [38, 39]. These cells may produce important growth 
factors, facilitate engraftment, or induce apoptosis. A number of nutrients, trace 
elements, and vitamins (zinc, selenium, copper, vitamins A, D, and E) are also 
critical to hematopoiesis. Retinoids and particularly retinoid antagonists play 




1.3 Characterization of HSC: 
HSC have an identity problem. First, the ones with long-term replicating ability 
are rare. Second, there are multiple types of stem cells and third, the stem cells 
look like many other blood or bone marrow cells. The most common approach 
is through markers that appear on the surface of cells. These are useful, but not 
perfect tools for the clinic and research laboratory [40, 41]. 
Phenotypically, murine HSCs are small cells with minimal cytoplasm, and they 
express high levels of the multidrug resistant (MDR) proteins and high levels of 
aldehyde dehydrogenase (ALDH) [42, 43].  
CD34 mainly expressed on a small fraction of human bone marrow cells. The 
CD34+ enriched cell population from marrow or mobilized peripheral blood 
appears responsible for most of the hematopoietic activity. CD34 has therefore 
been considered to be the most critical marker for hematopoietic stem cells 
(HSC). 
SCA-1+ (Stem cell antigen 1, Ly-6A/E) and C-kit+ (CD117) are hematopoietic 
marker for murine HSC. SCA-1 is the most recognized HSC marker in mice 
with both Ly-6 haplotypes as it is expressed on multipotent HSC . Sca-1+ HSC 
can be found in the adult bone marrow, fetal liver and mobilized peripheral 
blood and spleen within the adult animal. CD117 is a cytokine receptor 
expressed on the surface of hematopoietic stem cells. CD117 is an important 
cell surface marker used to identify certain types of hematopoietic (blood) 
progenitors in the bone marrow . It is also a marker for mouse prostate stem 
cells. 
The hematopoietic stem cells are negative for the markers that are used for 
detection of lineage commitment, and are, thus, called Lin-; and, during their 
purification by FACS, a bunch of up to 14 different mature blood-lineage 
marker, e.g., CD13 & CD33 for myeloid, CD71 for erythroid, CD19 for B cells, 
CD61 for megakaryocytic, etc. for humans; and, B220 (murine CD45) for B 
cells, Mac-1 (CD11b/CD18) for monocytes, Gr-1 for granulocytes, Ter119 for 
erythroid cells, CD3, CD4, CD5, CD8 for T cells etc. (for mice) antibodies are 
used as a mixture to deplete the lin+ cells or late multipotent progenitors (MPP). 
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Thy-1 can be considered as a surrogate marker for hematopoietic stem cells. It 
is one of the popular combinatorial surface markers for FACS for stem cells in 
combination with other markers like CD34. During sorting, mouse HSC fall 
under Thy1+/low subpopulation, while human HSC fall under the Thy1+ 
subpopulation. In humans, Thy-1 is only expressed on neurons [44]. Thy-1 is 
also a marker of other kind of stem cells, for example: mesenchymal stem cells, 
hepatic stem cells ("oval cells"), [45] keratinocyte stem cells [46]. 
There are many differences between the human and mice hematopoietic cell 
markers for the commonly-accepted type of hematopoietic stem cells. 
 
Mouse HSC: CD34lo/-, SCA-1+, Thy1.1+/lo, CD38+, C-kit+, lin- 





1.4 The importance of the HSC niche: 
Key properties of stem cells such as their self-renewal and developmental 
capacity can be controlled in a non autonomous manner by their cellular 
microenvironment. Such a microenvironment is usually referred to as a stem 
cell niche. A niche is a group of cells that allows a stem cell to maintain its 
identity [21]. The cells of a niche will prevent a previously specified cell from 
losing its stemness through loss of quiescence and potency or precocious 
differentiation. In the best demonstrations of a niche, a specific signaling 
pathway or a cell adhesion molecule is identified that allows the niche cells to 
maintain contact with stem cells and typically in the absence of such a 
mechanism, the stem cells leave their niche and either divide, differentiate, or 
apoptose [21]. 
The niche and the stem cells may arise from the same progenitor population, 
as is the case of the origin of HSC and endothelial cells of the dorsal aorta, 
which share a common progenitor in their ancestry [47], and the placenta in 
mice [48]. 
A niche could be derived completely separately from the stem cell, as is the 
case for the bone marrow hematopoietic niche, which utilizes signals derived 
from osteoblasts and mesenchymal stromal cells, both of which, although 
mesodermal, have different developmental origins from the HSC [49].In the 
mouse adult bone marrow, N-cadherin is expressed in the HSC and the 
spindle-shaped osteoblastic cells of the niche [50]. Mammalian hematopoiesis 
gives rise to long-term reconstituting HSC that, in turn, generate short-term 
repopulating HSC [51]. From these stem cells a number of more restricted 
progenitors emerge that give rise to all differentiated blood cells in adult 
circulation, such as lymphoid, myeloid, and erythroid cells [52]. Each of these 
progenitors can be distinguished by a subset of cell surface markers. 
Development of the initial definitive HSC requires Runx-1 [53], and its 
expression later continues in differentiating myeloid and lymphoid cells [54]. 
Later inactivation of Runx1 within the bone marrow is not essential for adult 
hematopoiesis, but it does affect maturation of lymphocytes and platelets [55]. 
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Osteoblast-specific loss of BMP-receptor 1 in mouse causes an increase in the 
number of osteoblasts and also a concomitant growth in the HSC pool [50]. The 
high calcium concentration present in the osteoblast niche is essential for 
homing and retention of HSC to this niche and for this purpose, HSC express 
the calcium-sensing receptor that enables them to respond to the calcium 
signal [56]. Osteopontin, produced by osteoblasts in response to various stimuli 
and secreted into the extracellular matrix is another important regulator of the 
number of HSC. Low levels of osteopontin lead to an increase in the number of 
HSC, suggesting that it is a negative regulator of stem cell number [57]. 
Conversely, targeting the osteoblasts with a suicide-gene causes metabolic 
death of the osteoblasts and also perturbs hematopoiesis [58]. Likewise, 
stimulation of the parathyroid receptor by overexpression of PTHPTHRP 
results in an increase in both the trabecular bone and the number of HSC [59]. 
Taken together these results identified the osteoblast as an integral component 
of the hematopoietic niche. More recently, a second niche, in relation to 
endothelial cells, has been identified and called the vascular niche [60, 61]. 
HSC interact with endothelial cells via signaling lymphocyte activation molecule 
(SLAM) receptors on sinusoidal cells both in the bone marrow as well as the 
spleen [62]. The current view is that perhaps the osteoblastic niche provides a 
quiescent environment for HSC maintenance while the vascular niche provides 
the environment required for differentiation and mobilization. 
The microenvironment in the stem cell niche is composed of cell-to-cell 
interactions via cell-surface molecule expression, chemokines and growth 
factors. This orchestra determines the fate of the cell(s) within the niche. The 
list of molecular mediators that regulate the HSC is increasing and includes 
angiopoietin-1/Tie-2, SDF-1 (CXCL12)/CXCR4, very late antigen 4 (VLA-4), 
leukocyte function antigen 1 (LFA-1), FGF-4, VEGF, SCF/c-kit, Wnt, N-cadherin 
and indirectly G-CSF, GM-CSF, FLT-ligand and possibly many others [63, 64, 
65]. 
It has been proposed that adhesive contacts through N-cadherin and 
Tie2/angiopoietin interactions hold the HSCs anchored to the endosteal niche 
promoting HSC quiescence [63]. C-myc has been shown to be an important cell 
intrinsic regulator required for HSC homeostasis regulating the release of HSC 
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from the quiescence-promoting niche. Upon conditional ablation of c-myc in 
bone marrow HSC, these stem cells are unable to differentiate as they increase 
adhesion molecules on their surface and remain anchored to the niche that 
retains them in a quiescent, undifferentiated state [66]. Although the osteoblast 
endosteal niche of the mouse bone marrow is so far the best characterized 
hematopoietic niche, the majority of the HSC that engraft in transplantation 
assays actually localize in perivascular spaces, in contact with sinusoidal 
venous endothelium [67], leading to the speculation that these surfaces may 
provide additional niche-like interactions for the maintenance of adult HSC. 
1.5 The clinical demand on HSC: 
Bone Marrow Transplantation (BMT) is a life saving procedure for a number of 
malignant and non-malignant life threatening diseases [68]. Ever since the first 
successful BMT in the late 1960s, an increasing number of BMT and related 
procedures are being performed world wide. Allogeneic stem cell (unrelated 
human leucocyte antigen, HLA identical donor) transplantation is now a 
curative treatment modality for a number of disorders, including malignant 
diseases, dyserythropoiesis, bone marrow aplasia, immunodeficiency states, 
and a number of inherited disorders [69]. 
The indications for hematopoietic stem cell transplantation [69] can be 
conveniently divided into two groups: (a) Malignant disorders: like leukemias, 
lymphomas, multiple myeloma and solid tumors like breast cancer, testicular 
cancer. In all these indications, the cure or palliation is by the high doses of 
chemotherapy or radiation therapy, while the transplant serves to rescue the 
patient from the myelotoxic effects of the anti-cancer therapy. In allogeneic type 
of transplants, there is an additional immunological advantage of graft vs 
cancer effect, which contributes to the disease relief; (b) Non-malignant 
diseases: like aplastic anemia, thalassemia, Gauchers disease, etc. In these 
conditions the abnormal marrow is deliberately destroyed and replaced by the 
healthy donor marrow. In this setting autologous (patients own stem cells) 
transplantation cannot be effective for obvious reasons. 
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Bone marrow and stem cell transplantation is curative in many potentially fatal 
conditions. The graft vs tumor effect seen after allogeneic transplants for 
human malignancies represents the clearest example of the power of the 
human immune system to eradicate cancer [70, 71]. It is likely that in future the 
high dose preparative regimens used in allogeneic bone marrow and stem cell 
transplants will be replaced with less toxic therapy leading to a safer transplant 
procedure. Autologous transplants are mainly done for lymphomas, solid 
malignancies like neuroblastoma and germinal cancers, hematological 
malignancies like multiple myeloma [72], and in patients with acute leukemia 
who do not have an HLA identical donor. The advantage of autologous 
transplant over allogeneic transplant is that there is no graft vs host disease 
(GVHD), and once engraftment occurs then graft rejection is unlikely. Thus 
there is a significant decrease in the complication rate as compared to the 
allogenic transplantation; however risk of tumor relapse is higher as compared 
to the allogeneic transplantation. 
 
1.6 Sources of HSC: 
1.6.1 Bone Marrow and Mobilized Peripheral Blood 
The best-known location for HSC is bone marrow, and bone marrow 
transplantation has become synonymous with hematopoietic cell 
transplantation. 
In adults, under steady state conditions, the majority of HSC reside in bone 
marrow. However, cytokine mobilization can result in the release of large 
numbers of HSC into the blood. As a clinical source of HSC, mobilized 
peripheral blood (MPB) is now replacing bone marrow, as harvesting peripheral 
blood is easier for the donors than harvesting bone marrow.  
1.6.2 Umbilical Cord Blood 
In the late 1980s, umbilical cord blood (UCB) was recognized as an important 
clinical source of HSC [73, 74]. Blood from the placenta and umbilical cord is a 
rich source of hematopoietic stem cells, and these cells are typically discarded 
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with the afterbirth. Increasingly, UCB is harvested, frozen, and stored in cord 
blood banks, as an individual resource (donor-specific source) or as a general 
resource, directly available when needed. Cord blood has been used 
successfully to transplant children and (far less frequently) adults. Specific 
limitations of UCB include the limited number of cells that can be harvested and 
the delayed immune reconstitution observed following UCB transplant, which 
leaves patients vulnerable to infections for a longer period of time. Advantages 
of cord blood include its availability, ease of harvest, and the reduced risk of 
graft-versus-host-disease (GVHD). In addition, cord blood HSC have been 
noted to have a greater proliferative capacity than adult HSC. 
 
1.6.3 Embryonic Stem Cells 
Embryonic stem (ES) cells form a potential future source of HSC. Both mouse 
and human ES cells have yielded hematopoietic cells in tissue culture [75]. 
However, recognizing the actual HSC in these cultures has proven problematic, 
which may reflect the variability in HSC markers or the altered reconstitution 
behavior of these HSC, which are expected to mimic fetal HSC. This, combined 
with the potential risks of including undifferentiated cells in an ES-cell-derived 
graft means that, based on the current science, clinical use of ES cell-derived 






2. CD44 Molecule 
CD44 is the most important molecule in the interaction between HSC and the 
osteogenic niche. The CD44 proteins form a ubiquitously expressed family of 
cell surface adhesion molecules that have a large extracellular domain, a 
transmembrane domain and an intracellular cytoplasmic domain. These 
molecules are termed adhesion since they bind strongly to specific ligands. 
This interaction is more complex in terms of sensing the extracellular 
environment and sending signals to adjacent cells. CD44, particularly its 
variants, may be useful as a diagnostic or prognostic marker of malignancy 
and, in at least some human cancers, it may be a potential target for cancer 
therapy [76]. 
CD44 glycoproteins are the major receptor to HA (Hyaluronic Acid) as the 
major ligand. HA is an extracellular polysaccharide present abundantly in 
extracelullar cell matrix (ECM) [77]. The CD44 epitope was first discovered as 
an antigen using a monoclonal antibody that was raised against human white 
blood cells [78]. It was then identified that a group of polymorphic proteins had 




CD44 is encoded by a single gene. It has 20 exons from which various protein 
products are further generated through alternative mRNA splicing. The 
standard form is most abundant and consists of an N-terminal signal sequence 
(exon 1), a hyaluron binding module (exon 2 and 3), a stem region (exon 4, 5, 
16 and 17), a single transmembrane domain (exon 18) and a cytoplasmic 
domain (exon 20). Alternative exon splicing of CD44 involves variable 
insertions of combinations of exons from 6-15, also known as variants 1-10 into 
the stem region. These variant isoforms of CD44 are seen mostly in epithelial 
cells and upregulated during diseases [79]. Little attention has been paid to 
isoforms that included exon 19, because RT-PCR studies revealed such 
transcripts are of very low abundance. 
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 2.2 Hyaluron binding, amino terminal domain 
In vitro studies have revealed that interaction of CD44 with hyaluronic acid 
(HA), collagen, laminin and fibronectin promote matrix dependent cell migration 
[78, 81]. However, there is no in vivo evidence. Apart from the hyaluron binding 
sites other sites have not been mapped precisely. A stretch of 90 amino acids 
in the amino terminal globular region form the link domain, that enables the 
binding of CD44 with HA and also other glycosaminoglycans (GAGs) [82, 83]. 
The affinity for GAGs depends on post translational modifications of CD44 such 
as glycosylations. More than one CD44 molecule binds to HA since only HA-
derived oligosaccharides larger than 20 residues bind to CD44 [84]. 
 
2.3 Stem structure 
The amino terminal globular domain of the smallest CD44 isoform (CD44 
standard) is separated from the plasma membrane by a 46 amino acids stem 
structure. It contains proteolytic cleavage sites. It also contains the variant exon 
region of CD44. The inclusion of several combinations of variant exons 
depends on mitogenic signals including stimulation of Ras-MEK-ERK pathway 
that regulate splicing events [85, 86] Some variant exon segments include 
motifs for post translational modifications but little is known about the exact 









2.4 Transmembrane and cytoplasmic domain  
The transmembrane and cytoplasmic domain are required for efficient ligand 
binding [87]. The transmembrane domain consists of 23 hydrophobic amino 
acids and a cysteine residue (Cys286) that seems to be involved in CD44 
oligomer formation. The cysteine residue is also responsible for recruiting CD44 
molecule into lipid rafts. Transmembrane region has also been proposed to be 
associated with distinct proteins in lipid rafts. However, the recruitment into lipid 
rafts is cell type specific. Some molecules like cadherins might be responsible 
for displacing CD44 from lipid rafts. The functional significance of this 
incorporation into lipid rafts is not well known [88]. 
The cytoplasmic domain is encoded by exon 19 or 20 and it has sites mediating 
interaction with ezrin, and also a putative ankyrin binding site. Intracellular 
association of CD44 with these cytoskeletal linker proteins could function in 
post-ligand binding events mediated by CD44. The cytoplasmic domain of 
CD44 may be phosphorylated at Ser325 and Ser291 residues [79], and this 
phosphorylation has been implicated in mediating cell migration on HA and in 
the interaction of CD44 with ezrin [89]. Intracellular partners of CD44 and motifs 
in the cytoplasmic domain are essential for subcellular localization for e.g. 
leading edge of lamellipodia of migrating cells as well as accessory functions of 
CD44 in signal transduction [78].  The cytoplasmic domain is known to promote 
Hyaluron internalization and thus migration of cells [90]. 
24
 
Scheme 4: CD44 domains [80] 
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2.5 CD44 Functions 
 
CD44 is widely expressed in different tissue types and has structural diversity 
that enables it to interact with several signaling molecules and facilitate various 
functional outcomes such as adhesion, migration, homing, proliferation, cell 
survival and apoptosis. These functions are discussed in detail below. 
2.5.1 Cell adhesion and migration 
 
Cell adhesion and migration are crucial for leukocytes and tumor cells in case 
of inflammation and metastasis, respectively. CD44 accumulates during several 
processes such as angiogenesis, wound healing and migration of cells across 
an HA substrate. HA being one of the important components of the ECM and 
CD44 being its receptor, this suggests an obvious role for CD44 in cell 
migration and adhesion [78]. Studies in a melanoma line transfected with CD44 
showed that these cells exhibit motility on HA coated surfaces. Accordingly, an 
isoform of CD44 that does not bind to hyaluronic acid is not able to promote 
migration on HA. In addition, antibodies blocking the HA binding site of CD44 
were able to block the migration of these cells [87].  
Leukocytes and metastasizing tumor cells need to migrate and localize in 
special tissues and microenvironments for their functions and nutrition in the 
case of tumor cells [91]. Rolling of cells is generally mediated by selectins and 
carbohydrate ligands where they promote leukocyte entry into sites of 
inflammation [92]. In addition it is also mediated by CD44 and HA interactions. 
These processes are mediated by CD44v4-v7 isoforms as well as by different 
glycosylation patterns of CD44. CD44 gets localized at the leading edge of the 
cell and in lamellipodia showing evidence for cytoskeletal anchoring of CD44 on 
an HA matrix. Metalloproteinase bound protein of type-1(MT1-MMP) is 
recruited into lamallipodia through CD44. MT1-MMP in turn cleaves CD44 and 
allows new CD44-HA interactions during which migration of cells takes place. 
This process is mediated through Ras, PI3K (phosphoinositide 3-OH kinase), 
cdc42/Rac and serine proteases might also support CD44-mediated cellular 
mobility by cleavage of the molecule [93-96].  
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Endothelial cells bind to HA through their CD44 molecules and proinflammatory 
cytokines such as tumor necrosis factor (TNF) and interleukin-1く (IL-1 く) 
stimulate CD44 thus strengthening the endothelial cell HA binding and 
mediating leukocyte extravasation.  Leukocyte immigration into sites of 
inflammation and delayed type hypersensitivity reactions can be inhibited using 
antibodies specific for CD44. It has been proposed that IM7 (anti-CD44) binds 
to CD44 and reduces its expression on leukocytes and induces proteolytic 
cleavage of CD44 thus blocking migration. [97] Antigen presenting cells, 
Langerhans cells and dendritic cells up regulate CD44 variants v4, v5, v6 and 
v9 and these epitopes of CD44 are essential in binding to T cells in the lymph 
nodes. Antibodies against these isoforms of CD44 block the migration of these 
antigen presenting cells [98]. 
2.5.2 Interaction with the cytoskeleton 
 
Reorganisation of the cytoskeleton is important for cell migration and other 
physiological processes. Since the cytoplasmic domain of CD44 does not have 
actin binding sites, CD44 binds to the actin cytoskeleton through cytoskeleton 
associated proteins ankyrin, ERM family of proteins (ezrin, radixin and moesin) 
and related protein merlin [99]. 
Ankyrin is a group of homologous proteins that is involved in segregation of 
integral membrane proteins that have their functional domain on the plasma 
membrane and is mainly involved in linking cytoplasmic domains of integral 
membrane proteins to spectrin-actin based membrane cytoskeleton. Ankyrin 
has several isoforms generated through alternative gene splicing and different 
gene products coding for the protein. This is how the protein can bind several 
membrane proteins and mediate diverse interactions with cytoskeleton [100]. 
CD44 binds to ankyrin cytoskeletal protein linking the plasma membrane to 
underlying cytoskeleton. CD44 gets phosphorylated by protein kinase C. These 
two post translation modifications enhance the binding of CD44 to ankyrin. The 
binding affinity is further enhanced through GTP binding proteins [101-103]. 
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ERM are band 4.1 superfamily proteins acting as key linkers between 
transmembrane proteins and cytoskeleton.  The ERM proteins have a 300 
amino acid domain at the N-terminus, g-helical central region and a C-terminal 
domain which has the F-actin binding site. ERM proteins are activated by 
phosphorylation and by binding to membrane phospholipids. It is the 
phoshorylated (active) form of ERM that binds to CD44 [99]. ERM activation is 
regulated via Rho GTPase family. Binding of ROK, PKC and phosphatidyl 
inositol 4,5 bisphosphate (PIP2) to ERM proteins results in phosphorylation of 
these proteins [104-106]. Thr567 Ezrin, Thr564 Radixin and Thr558 Moesin 
phosphorylations result in rearrangement of the cytoskeleton [107]. CD44 
binding to cytoskeleton is further regulated by its cytoplasmic domain. In resting 
cells CD44 is phosphorylated at Ser325. The switch from Ser325 
phosphorylation to Ser291 is triggered via PKC and leads to a break in the 
association between ezrin and CD44. In addition, Ser291 phosphorylation is 
also involved in directional migration of cells. How exactly CD44 is 
phosphorylated and dephosphorylated is yet to be determined. But, CD44 
binding to HA triggers various signaling pathways including activation of PKC. A 
good example is ezrin that associates with PKC and thus promotes 
phosphorylation of CD44 and regulates binding to the cytoskeleton [89].  
 Merlin is a member of 4.1 protein ERM family that has 65% homology to ERM 
proteins. Its activity is also regulated through phosphorylation and 
dephosphorylation [108]. Merlin does not have an actin binding site and merlin-
CD44 complex cannot bind to cytoskeleton (Morrison, Sherman et al. 2001). 
The ability of ERM/merlin proteins to switch between phosphorylated and 
dephosphorylated forms along with the competition between ERM and merlin to 
bind to CD44 leads to making and breaking of CD44 interactions with the 
cytoskeleton [89]. When cells are in the growth phase phosphorylated ERM 
binds to CD44 mediating cytoskeletal interactions. During this time merlin gets 
phosphorylated by PAK2 (p21-active kinase -2) and is now unable to bind to 
CD44. During growth arrest the opposite is seen and MAPK activation is 
blocked [109, 110]. 
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2.5.3 Interaction with cytokines, chemokines and enzymes 
 
Apart from interacting with extracellular matrix (ECM), CD44 also interacts with 
extracellular proteins and harbors growth factors. CD44 molecules have two 
consensus sequences in exon 5 and variant 3 exon which allow increased 
binding of interferon-け and osteopontin, thus suppressing proliferation and 
inducing MHC-II expression [111]. CD44v3 has been shown to immobilize 
chemokines such as osteopontin, scatter factor, endothelial growth factor, MIP-I 
く and RANTES, reviewed in [80]. 
Cytokines play an essential role in regulating hematopoiesis that is regulated by 
interaction between bone marrow microenvironment and progenitor cells. 
Antibodies against CD44 v4 and v6 stimulate the production of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) [112]. 
Extracellular matrix degrading enzymes are required during tissue remodeling, 
wound healing, angiogenesis and tumor progression. CD44 plays a role by 
harboring matrix metalloproteinases such as MMP2 and MMP9 at the cell 
surface. CD44 monoclonal antibody has been shown to upregulate the 
expression of MMP-2 which would have implications in tumor metastasis, 
growth and lymphocyte function. [113] 
CD44 binds to the chemokine, osteopontin. CD44 binding to osteopontin results 
in downregulation of the anti-inflammatory cytokine IL-10 and survival of cells 
by IL-3 and GM-CSF cytokines. These two cytokines share a common beta 
subunit and the distal cytoplasmic tail participates in cell survival. Binding to 
osteopontin also activates PI3K and Akt and thus is involved in the survival 
pathway of IL-3 [114]. 
CD44v3 heparan sulphate proteoglycan and v6 bind to epidermal growth factor, 
heparin binding epidermal growth factor and fibroblast growth factor and 
present in an efficient way to their receptors for survival and proliferation of 
leukocytes and tumor cells. One example is CD44v3 heparan sulphate 
proteoglycan that recruits proteolytically active MMP-9 and heparin binding 
epidermal growth factor precursor (pro-HB-EGF) that in addition activates its 
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receptor ErbB4 which is involved in cell survival. [115] CD44v3 isoform 
efficiently binds to hepatocyte growth factor/scatter factor (ligand for receptor 
tyrosine kinase) through its heparin sulphate chain. The functional outcome is 
promotion of c-met phosphorylation, MAPK activation and increased tumor 
growth and metastasis [116]. 
Taken together the binding of cytokines, enzymes and chemokines to CD44 is 
essential for organogenesis, hematopoesis, inflammatory and autoimmune 
responses and tumor progression. 
2.5.4 CD44 as a co-receptor and signaling  
 
Many if not all signaling events are initiated through extracellular stimuli, 
followed by activation of receptor tyrosine kinases (RTKs).  These receptors 
span the plasma membrane and their cytoplasmic domains have catalytic 
kinase activities that get phosphorylated upon ligand binding or other sources 
of stimulation and further serve as docking sites for several components of 
intracellular signaling. Receptor activation is mediated by several other proteins 
that are associated with them and which are devoid of catalytic activity (co-
receptor activity). Cell adhesion molecules are now being known for their co-
receptor activity [117] and CD44 is one of them.  CD44 acts as a co-receptor 
for the ErbB family of receptor tyrosine kinases and for the c-Met receptor, and 
these associations are essential for activation of receptor kinase activity and 
the regulation of diverse cellular processes, including cell survival, proliferation 
and differentiation. 
Since cytoskeletal organization and cell migration have been dealt with in the 
previous sections this section will mainly focus on cell growth proliferation, 




Scheme 5: Signaling mediated by CD44 [77]
One main reason for the involvement of CD44 in multiple signaling events is its 
association with the Src family of phosphotyrosine kinases (PTKs). Src kinases 
act as molecular switches on the cell membranes linking extracellular events to 
intracellular signaling.  They are activated through engagement with many 
receptors such as TCR/CD3 complex, CD4, CD8, B cell receptor, Fc receptors, 
integrins, GPI anchored receptors and growth factor receptors, reviewed in [80]. 
When activated (they are also phosphorylated on regulatory tyr residue c-
terminal when inactive) they mediate several signaling events including 
activating of additional PTKs such as ZAP-70 or Syk, phospholipases, 
cytoskeletal proteins and adaptor proteins.  
CD44 signaling can result in opposing effects depending on the cellular context, 
the expressed variant isoform and the associated signaling partner. For 
example, CD44 engagement can lead to proliferation or inhibition of 
proliferation, apoptosis or inhibition of apoptosis, resulting in up regulation and 




Scheme 6: Accessory functions and signaling via CD44 [118] 
CD44 associates with Lck and Lyn Src kinases in non stimulated T and B cells. 
It was shown that synthetic peptide of CD44, pCD44 (ILAVCIAVNSRRR) has 
high binding capacity towards these Src kinases. This peptide region 
corresponds to plasma membrane-cytoplasmic domain interface of CD44. A 
single mutation in the cysteine residue is enough to abolish the interaction 
[119]. Src kinase co-translocate with CD44 by binding to CD44 carboxyl-
terminal ankyrin domain which in turn facilitates integrin く1 recruitment and 
activation in lipid rafts and mediates matrix derived  cell survival [120]. 
Signaling of CD44 mediated through its association with Lck leads to 
phosphorylation of Pyk2, a focal adhesion kinase which leads to cytoskeleton 
reorganization and cell spreading [121].  
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T cell activation requires two signals one from the TCR and the other from a co-
stimulatory molecule. CD44 has been described to deliver co-stimulatory 
signals for T cell activation [122]. CD44 and the associated Lck are recruited 
into membrane microdomains (low density sucrose gradient fractions) where 
they interact with the CD3/TCR complex. Association of CD44 with Lck and Fyn 
and in turn their co-localisation with the TCR allow for recruitment of several 
other kinases necessary for T cell activation [122, 123].  The co-stimulatory 
function of CD44 is demonstrated by its ability to induce cell proliferation on 
freshly isolated lymph node cells in the presence of sub-threshold levels of anti-
CD3. This is mediated by activation of several tyrosine kinases and is 
accompanied by strong activation of erk and c-jun and involvement of MAPK. 
Consequently, IL-2 production and CD69 and CD25 expression are up 
regulated in T cells. The situation differs in the T helper line IP-12 where it was 
observed that CD44-cross-linking with CD3 leads to upregulation of CD95 and 
CD95L expression resulting in apoptosis induction (or activation induced cell 
death (AICD). This argues for the differential effects of CD44 on different cell 
types. It is important to note that, in both peripheral T cells and T helper line 
(IP12) CD44 cross linking alone did not exert any effect on signaling by itself 
[122].  
The effects of anti-CD44 Ab treatment are specific for the epitope of CD44 
where it binds i.e. co-stimulatory functions of CD44 inducing proliferation or 
apoptosis are exhibited only by cross-linking with IM-7 that does not bind to 
hyaluron binding site and not by KM81 binding to hyaluron binding domain of 
CD44 or K926 that binds to CD44v10 [122]. Some studies have shown that 
CD44 by itself is capable of activating human resting T cells and mouse 
cytotoxic T cells by itself like CD3 and can promote proliferation of T cells that 
is dependent on IL-2 production. In this study, anti-CD44 cross-linking does not 
phosphorylate the Zeta chain of the TCR complex indicating that the signals 
generated in this case are independent of TCR engagement. Indeed, it was 
demonstrated that  this process is mediated by tyrosine kinases associated with 
CD44 [124]. In a TNBS-induced colitis mouse model, CD44v7 was shown to 
deliver anti-apoptotic signals and protect T cells from activation induced cell 
death. Cells were protected from apoptosis by upregulation of anti-apoptotic 
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proteins Bcl-2 and Bcl-xl and down regulation of CD95L [125]. It was also 
demonstrated in this work that the anti-apoptotic effect of CD44v7 is mediated 
via Akt and phosphorylation of the pro-apoptotic molecule Bad [125].  
Using a mouse model for the autoimmune disease alopecia areata Marhaba et 
al., have shown an association between CD44 and CD49d. This association 
resulted in the formation of a signaling complex between CD44, CD49d and the 
underlying signaling machinery allowing for each surface molecule (CD44 or 
CD49d) to avail from the associated signaling molecules of the other. In this 
case, cross-linking of CD44 resulted in the activation of the focal adhesion 
kinase (FAK) associated with CD49d, and CD49d cross-linking allowed the 
activation of Ezrin and Lck associated with CD44. Thus signaling pathways 
initiated through both the molecules CD44 and CD49d are triggered and this is 
important in lymphocyte activation and function [126]. 
CD44 signaling also mediates proliferation and apoptosis in several tumor lines 
depending on the cell type and engagement of CD44 isoform. The Src-kinase 
Lyn, was found to be activated via CD44v6 in a colorectal cancer cell line. The 
functional consequence was increased chemoresistance against the drug 1,3-
bis (2-chloroethyl)-1-nitrosurea and this was mediated through the PI3K/Akt 
survival pathway [127]. In an ovarian tumor, CD44 association with c-Src was 
responsible for cytoskeletal reorganization mediated by phosphorylation of the 
cytoskeletal protein cortactin leading to increased migration and spreading 
[128]. A thymoma line (EL4) transfected with CD44v6 was subjected to much 
higher proliferation rates as compared to untransfected cells that express only 
CD44 standard isoform. Signaling molecules, erk, c-jun were activated and IkB 
was phosphorylated suggesting NF-kB activation. Indeed, NF-せB was found to 
be translocated to the nucleus. Consequently, IL-2 production was increased 
[129].  
On the other hand, CD44 was also shown to strengthen dexamethasone 
induced apoptosis of a lymphoma line that was mediated through up regulation 
of the pro-apoptotic protein Bax and down regulation of the anti-apoptotic 
protein Bcl-Xl. The same effect by CD44 was also seen in thymic epithelial cells 
mediating apoptosis of a lymphoma line [130]. CD44 cross-linking in fibroblast 
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drives cells into apoptosis suggesting a role for CD44 in fibroblasts control 
[131]. CD44 ligation induced apoptosis of a promyelocytic leukemia line. 
Apoptosis was initiated via caspase 8 and 9 and in addition effector caspase 3 
and 9. Serine protease dependent pathway was also proposed to be involved in 
mediating apoptosis of these cells [132].  
With respect to tumors, it has been proposed that HA-CD44 interaction 
mediates proliferation and soluble CD44 inhibits the growth of cells. When a 
murine mammary cell line was transfected with soluble CD44, it was observed 
that the cells no longer attached to the peritoneal wall and also did not form 
tumors. This led to inhibition of anchorage dependent growth as well as tumor 
invasion. [133] CD44-HA interaction also promotes neo-angiogenesis and 
proliferation. Hyaluronic acid dependent clustering of CD44 promotes binding of 
MMP-9 to CD44 at the cell surface promoting its activity in addition to protecting 
it from tissue inhibitors for MMPs and thus promoting tumor invasion and 
angiogenesis [134]. 
One of the main events mediated by CD44 is cytoskeletal organization which is 
energy dependent and requires an intact actin and microtubuli system. Small 
GTPase Rac1 activation is required for this process. Rac1 is also known to co-
localise with ezrin [135]. These events along with phosphotyrosine kinase 
activations are responsible for cytoskeletal re-organizations in the cell. In T 
lymphocytes cross-linking anti-CD44 Ab leads to CD44 dependent spreading 
through F-actin polymerization, accompanied by T cell adhesion, flattening and 
spreading [123]. Vav1 protein encoded by vav protooncogene is a 95KD protein 
that is an upstream regulator of Rac1. Vav catalyses the GDP to GTP 
exchange on Rac1. Vav1 activation involves phosphoinositides binding and 
tyrosine phosphorylation that is dependent on Src family kinases (Lck and Fyn) 
which associate with CD44. Thus, this could be a possible explanation for 
CD44 mediated effects on the cytoskeleton [123, 136, 137]. CD44 is co-
localized in membrane microdomains (lipid rafts) where it interacts with Annexin 
II in a cholesterol dependent manner. The recruitment of CD44 in rafts further 
leads to stabilization of actin-cytoskeleton [138]. 
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2.6 CD44 in Hematopoietic Stem Cells: 
CD44 is important for Hematopoietic stem cell homing. Bone marrow stroma 
formation also requires CD44 that supports the process by induction of IL-6 
secretion. Human and mouse HSC synthesize and express HA and HA 
expression correlates with selective migration of HSC to the endosteal niche. 
HSC homing can be blocked by anti-CD44 or soluble HA or hyaluronidase 
treatment. In addition, CXCL12 stimulates adhesion of progenitor cells via 
CD44, which demonstrate a cross-talk between CD44 and CXCR4 signaling 
and suggest a key role of HA and CD44 in CXCL12-dependent transendothelial  
migration of HSC and their anchorage within specific niches. Thus, CD44 
contributes to homing and settlement of HSC in the bone marrow niche.  
Taken together, the involvement of CD44 in HSC homing and niche embedding 
is known since over a decade and has been used as a means to mobilize HSC. 
Meanwhile, compelling evidence has been provided that LSC compete with 
HSC for embedding in the bone marrow niche and that LSC may be driven into 
differentiation or apoptosis by anti-CD44, which prevents their homing in the 














CD44 has been identified as a leukemia initiating cell marker on several types 
of hematological malignancies. CD44 expression on hematopoietic stem cells 
(HSC) is required for homing into the osteogenic niche and maintenance of 
quiescence. CD44 plays an important role in leukemic stem cells (LSC) and 
hematopoietic stem cells (HSC) niche embedding, LSC and HSC apparently 
compete and a blockade of CD44 more efficiently prevents HSC than LSC 
embedding during HSC reconstitution. 
Based on these findings and in view of the importance of CD44 for 
hematopoiesis we aimed to evaluate: 
The CD44 isoform and associating molecules on HSC, leukemic cells and BM    
stroma cells, that contribute to the adhesion process. 
The CD44 ligands on HSC, leukemic cells or BM stromal cells and their impact 

















Mice  Origin 
C57BL6 (H-2b) Wild type Charles River, Suzfeld, 
Germany 
Balb/c Wild type Charles River, Suzfeld, 
Germany 
 
2.1.2 Bacterial strain 
E.coli DH5g       Genotype: F-, f80dlacZ〉M15, 〉(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rk-
,mk+), phoA, supE44, thi-1, gyrA96, rel A1, そ- 
(Invitrogen, Darmstadt, Karlsruhe) 
 
 
2.1.3 Cell Lines 
Cell Line Origin 
EL-4 Mouse Thymoma American Type Tissue Culture 
(ATCC) number: TIB- 39 
EL-4 transfected with CD44v6 [129] 
HEK 293-EBNA 1 ATCC number: CRL-1573 derived; transfected with 
the EBNA1 viral gene. 
Myc -9e10 mAB-9e10 producing hybridoma line ATCC CRL 
1975 
IM7.8.1 mAb IM7.8.1 producing hybridoma line ATCC 
TIB235 
PS/2 mAb  PS/2  producing hybridoma line ATCC 
S17 Established from the adherent layer of Dexter-type 
long-term bone marrow cultures. 
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2.1.4 Primers 
F   5-GATCCATGAGTCACAGTGCG-3 CD44s 
R  5-GCCTACTGGAGATCAGGATG-3 
F  5-AGTCAAATACCAACCCAACAGG-3 CD44v3 
R  5-TGGTACTGGAGATAAAATCTT-3 
F   5-CTCCTAATAGTACAGCAGAA-3 CD44v6 
R  5-CAGTTGTCCCTTCTGTCA-3 
F  5-CTTCGGCCCACAACAACCAT-3 CD44v7 
R 5-CCTTGCTTTCTGTTTGATGAC-3 
F 5-ATACAGACTCCAGTCATAGTACAA-3 CD44v8 
R 5-GAGTTGTCACTGAAGTGGTC-3 
F 5-CACAGAGTCATTCTCAGAACT-3 CD44v9 
R 5-TGCTAGATGGCAGAATAGAAG-3 
F 5-TGCAAGAAGAGGTGGAAGTCTTCC-3 CD44v10 
R 5-CTGGTAAGGAGCCATCAACATTAA-3 
F 5-GACCCCTTCATTGACCTCAAC-3 GAPDH 
R 5-CTTCTCCATGGTGGTGAAGAC-3 
 
2.1.5 Primary Antibodies 
Antibody Company  
Anti-CD11a Becton Dickinson, Heidelberg, Germany 
Anti-CD11b/YBM6.6.10 European Association of Animal Cell Cultures 
Anti-CD11c European Association of Animal Cell Cultures 
Anti-CD16 Immunotools, Friesoythe, Germany 
Anti-CD18 Becton Dickinson, Heidelberg, Germany 
Anti-CD24 Becton Dickinson, Heidelberg, Germany 
Anti-CD30 Becton Dickinson, Heidelberg, Germany 
Anti-CD31 Becton Dickinson, Heidelberg, Germany 
Anti-CD34 Becton Dickinson, Heidelberg, Germany 
Anti-CD38 Becton Dickinson, Heidelberg, Germany 
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Anti-CD43 Becton Dickinson, Heidelberg, Germany 
Anti-CD44(IM7) ATCC 
Anti-CD44v6 Bender Medsystems 
Anti-CD44v7 Calbiochem, Darmstadt, Germany 
Anti-CD44v10 (K926) [163] 
Anti-CD45R Becton Dickinson, Heidelberg, Germany 
Anti-CD49a Becton Dickinson, Heidelberg, Germany 
Anti-CD49b Becton Dickinson, Heidelberg, Germany 
Anti-CD49d (PS/2) Miyazaki et al  
Anti-CD49e Becton Dickinson, Heidelberg, Germany 
Anti-CD49f Becton Dickinson, Heidelberg, Germany 
Anti-CD51 Becton Dickinson, Heidelberg, Germany 
Anti-CD53 Becton Dickinson, Heidelberg, Germany 
Anti-CD54 (YN1/1.7.4) European Association of Animal Cell Cultures 
Anti-CD61 Becton Dickinson, Heidelberg, Germany 
Anti-CD62E Becton Dickinson, Heidelberg, Germany 
Anti-CD62L Immunotools, , Friesoythe; Germany 
Anti-CD62L-lig Becton Dickinson, Heidelberg, Germany 
Anti-CD62P Becton Dickinson, Heidelberg, Germany 
Anti-CD71 Becton Dickinson, Heidelberg, Germany 
Anti-CD81 Becton Dickinson, Heidelberg, Germany 
Anti-CD90 Immunotools, , Friesoythe; Germany 
Anti-CD95 Becton Dickinson, Heidelberg, Germany 
Anti-CD95l Becton Dickinson, Heidelberg, Germany 
Anti-CD102 Becton Dickinson, Heidelberg, Germany 
Anti-CD103 Becton Dickinson, Heidelberg, Germany 
Anti-CD104 Becton Dickinson, Heidelberg, Germany 
Anti-CD105 Becton Dickinson, Heidelberg, Germany 
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Anti-CD106 Becton Dickinson, Heidelberg, Germany 
Anti-CD117 Becton Dickinson, Heidelberg, Germany 
Anti-CD123 Becton Dickinson, Heidelberg, Germany 
Anti-CD126 Becton Dickinson, Heidelberg, Germany 
Anti-CD127 Becton Dickinson, Heidelberg, Germany 
Anti-CD184 Becton Dickinson, Heidelberg, Germany 
Anti-CD195 Becton Dickinson, Heidelberg, Germany 
Anti-CD209 Becton Dickinson, Heidelberg, Germany 
Anti-CD284 Biolegend,  Uithoorn, Netherlands 
E13 ATCC 
Anti-Flt3 Santa Cruz, Heidelberg, Germany 
Anti-Gr1 Immunotools, , Friesoythe; Germany 
Anti-GMCSF Becton Dickinson, Heidelberg, Germany 
Anti-SDF1 Becton Dickinson, Heidelberg, Germany 
Anti-Trail Becton Dickinson, Heidelberg, Germany 
Anti-TNFRI Becton Dickinson, Heidelberg, Germany 
Anti-TNFRII Becton Dickinson, Heidelberg, Germany 
Anti-Ter119 Becton Dickinson, Heidelberg, Germany 
Anti-Ly6 Becton Dickinson, Heidelberg, Germany 
Anti myc ATCC 
Anti-IL-3 Becton Dickinson, Heidelberg, Germany 
Anti-IL-7 Bio Trend, Dortmund, Germany 
Anti-pAkt Becton Dickinson, Heidelberg, Germany 
Anti-akt Becton Dickinson, Heidelberg, Germany 
Anti-Actin Becton Dickinson, Heidelberg, Germany 
Anti-Bax Becton Dickinson, Heidelberg, Germany 
Anti-Bcl2 Becton Dickinson, Heidelberg, Germany 
Anti-BAD Becton Dickinson, Heidelberg, Germany 
41
Anti-pBAD Cell Signalling, Frankfurt , Germany 
Anti-Caspase 3 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 9 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 9 cleaved Cell Signalling, Frankfurt , Germany 
Anti-Casein Kinase 2 Becton Dickinson, Heidelberg, Germany 
Anti-Cytochrome C Becton Dickinson, Heidelberg, Germany 
Anti-pERK1/2 Santa cruz, Heidelberg, Germany  
Anti-ERK1/2 Becton Dickinson, Heidelberg, Germany 
Anti-Histone H3 Cell Signalling, Frankfurt , Germany 
Anti-NFkB Santa Cruz, Heidelberg, Germany 
Anti-pIkB Cell Signalling, Frankfurt , Germany 
Anti-PP1 Cell Signalling, Frankfurt , Germany 
Anti-PP2a Cell Signalling, Frankfurt , Germany 
Anti-phosphothreonine (pThr) Santa Cruz, Heidelberg, Germany 
Anti-phosphotyrosine (py20) Becton Dickinson, Heidelberg, Germany 
 
 
2.1.6 Secondary antibodies 
Name Company 
Anti-mouse IgG HRP Amersham, Freiburg, Germany 
Anti-rabbit IgG HRP Amersham, Freiburg, Germany 
Anti-rat IgG HRP Amersham, Freiburg, Germany 
Anti-mouse IgG PE Jackson Laboratories, Bar Harbor,USA 
Anti-hamster IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-mouse IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-mouse IgG APC Jackson Laboratories, Bar Harbor,USA 
Anti-rat IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-rat IgG PE Jackson Laboratories, Bar Harbor,USA 
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Anti-rat IgG APC Becton Dickinson  Heidelberg, Germany 
Streptavidin FITC Jackson Laboratories, Bar Harbor,USA 
Streptavidin PE Jackson Laboratories, Bar Harbor,USA 
Streptavidin APC Jackson Laboratories, Bar Harbor,USA 
Streptavidin HRP Rockland, PA USA 
 
2.1.7 Inhibitors and Enzymes 
MEK1/2 Inhibitor (SL327) Calbiochem, Darmstadt, Germany 
 
Caspase 9 Inhibitor          
 
Calbiochem, Darmstadt, Germany 
 
CK2 Inhibitor                    Calbiochem, Darmstadt, Germany 
 
Restriction enzymes  MBI Fermentas, St. Leon-Rot, Germany 
Taq polymerase MBI Fermentas, St. Leon-Rot, Germany 
 
2.1.8 Instruments 
Name  Company 
Agitator for bacterial cultures Edmund Buehler GmbH, Hechingen, 
Germany 
Cell chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge Sorvall RC5B Plus Kendro, USA 
Centrifuge Biofuge fresco Heraeus, Hanau, Germany 
DNA-agarose gel electrophoresis 
chamber 
Bio-Rad, Munich, Germany 
Eagle eye (Mididoc) Herolab, Wiesloch, Germany 
ELISA plate reader Anthos labtec, Wals, Austria 
FACS  Calibur Becton-Dickinson, Heidelberg, Germany 
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Hyper processor (for processing films) Amersham, Freiburg, Germany 
Incubator for bacteria Melag, Berlin, Germany 
Incubator for cell culture Labotec, Goettingen, Germany 
Invert microscope DM-IL Leica, Bensheim, Germany 
Master cycler (PCR cycler) Eppendorf, Hamburg, Germany 
Magnetic stirrer 3000 Heidolph, Keilheim, Germany 
Microscope DMBRE Leica, Bensheim, Germany 
Microwave Phillips, Wiesbaden, Germany 
Photocassette Amersham, Freiburg, Germany 
Ph-Meter-761 Calimatic Knick, Berlin, Germany 
Photometer Ultraspec III Amersham, Freiburg, Germany 
Pipettus-Akku Hirschmann, Eberstadt, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Powersupply PS 9009 GIBCO, Darmstadt, Germany 
Rotor GSA Kendro, USA 
Rotor SW34 Kendro, USA 
Rotor SW41 Ti Beckman Coulter, Krefeld, Germany 
Sterile bench Heraeus, Hanau, Germany 
Sonicator Sonoplus Bandelin, Berlin, Germany 
Tabletop centrifuge Heraeus, Hanau, Germany 
Transferapparatus Mini Trans-Blot® Bio-Rad, Munich, Germany 
Thermo-mixer Eppendorf, Hamburg, Germany 
Ultrasound homogenizer Bandelin Electronik, Germany 
Water-bath Julabo, Seelbach, Germany 
Weighing scale RC210 D Sartorius, Goettingen 
Whirlmixer Vortex Genie Si Inc., New York, USA 
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2.1.9 Miscellaneous Materials 
Cell culture flasks 25cm2, 75cm2 Greiner, Frickenhausen, Germany 
Cell culture 96-well, 24-well, 6-well 
plates 
Greiner, Frickenhausen, Germany 
Centrifugal concentrators Vivaspin 
6ml, 20ml 
Vivascience, Hannover, Germany 
Cryovials Greiner, Frickenhausen, Germany 
Coverglass R. Langenbrinck, Emmendingen, 
Germany 
CFSE Invitrogen, Frankfurt, Germany 
Falcon tubes 15ml, 50ml Greiner, Frickenhausen, Germany 
Hyaluronan SIGMA, Steinheim, Germany 
Hyperfilm ECL Amersham, Freiburg, Germany 
Magnetic Beads Miltenyl Biotec,  Bergisch Gladbach, 
Germany 
Needles BD Biosciences, Heidelberg, Germany 
Nitrocellulose membrane Hybond ECL Amersham, Freiburg, Germany 
Parafilm American Nat. Can., Greenwich, Great 
Britain  
Petriplates Greiner, Frickenhausen, Germany 
Pipette tips Sarstedt, Numbrecht, Germany 
Sterile filter 0,2µm Renner, Darmstadt, Germany 
Syringes BD Biosciences, Heidelberg, Germany 
Trans-well migration (Boyden) 
chambers 48 well 
Neuroprobe, Gaithusberg, USA 








Acetic acid Riedel-de Haen, Seelze 
Acetone Fluka, Buchs, Switzerland 
Agarose Sigma, Steinheim 
Ammonium persulphate (APS) GIBCO, Darmstadt 
Ampicillin sulphate Calbiochem, Darmstadt 
Annexin FITC V Becton Dickinson,Heidelberg 
Bactoagar Fluka, Buchs, Switzerland 
Bio-Rad, Munich Bradford reagent Bio-Rad, Munich 
Biotin-X-NHS Calbiochem, Darmstadt 
Bovine Serum Albumin (BSA) PAA, Pasching, Austia 
Brij 96 Fluka, Buchs, Switzerland 
Bromo phenol blue Merck, Darmstadt 
Calcium chloride Merck, Darmstadt 
CFSE Invitrogen, Darmstadt 
Chloroform Riedel-de Haen, Seelze 
Coomassie R-250 Merck, Darmstadt 
Crystal violet Sigma, Steinheim 
Dimethyl formamide Merck, Darmstadt 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
Ethanol Riedel-de Haen, Seelze 
Ethidium bromide Merck, Darmstadt 
Ethylenediamine tetraacitic acid (EDTA) Sigma, Steinheim 
Foetal Calf Serum (FCS) PAA, Pasching, Austria 
Formaldehyde (37%) Merck, Darmstadt 
G418 sulphate  PAA, Pasching, Austria 
Gelatine (cold water fish skin) Merck, Darmstadt 
Glucose Merck, Darmstadt 
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Ladder Gen ruler  Protein  MBI Fermentas, St. Leon-Rot 
Ladder Prestained Protein  MBI Fermentas, St. Leon-Rot 
L-Glutamine AppliChem, Darmstadt 
Glycerine Roth, Karlsruhe 
Glycine GERBU, Gaiberg 
HEPES GERBU, Gaiberg 
HiPerfect-Reagent for transfection Quiagen, Hilden 
Hydrochloric acid (HCl) Riedel-de Haen, Seelze 
Hygromycin PAA, Pasching, Austria 
Isopropanol Fluka, Buchs, Switzerland 
Magnesium carbonate Merck, Darmstadt 
Magnesium chloride Merck, Darmstadt 
Magnesium sulphate Merck, Darmstadt 
Milk powder Roth, Karlsruhe 




Paraformaldehyde Sigma, Steinheim 
Penicillin Sigma, Steinheim 
Phenylmethylsulphonylfluoride (PMSF) Sigma, Steinheim 
Phorbolmyristateacetate (PMA) Sigma, Steinheim 
Potassium acetate Sigma, Steinheim 
Potassium carbonate Roth, Karlsruhe 
Potassium chloride Merck, Darmstadt 
Potassium dihydrogenphosphate Merck, Darmstadt 
Potassium tetrathionate Merck, Darmstadt 
Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim 
Protein G Sepharose 4 Fast Flow Amersham Biosciences, Freiburg  
Rotipherose Gel 30 (Acrylamide-mix) Roth, Karlsruhe 
47
RPMI 1640 GIBCO, Darmstadt cell culture 
Silver nitrate Roth, Karlsruhe 
Sodium acetate Merck, Darmstadt 
Sodium azide AppliChem, Darmstadt 
Sodium carbonate AppliChem, Darmstadt 
Sodium chloride Fluka, Buchs, Switzerland 
Sodium hydrogen phosphate Merck, Darmstadt 
Sodium dodecyl sulphate (SDS) GERBU, Gaiberg 
Sodium hydrogen carbonate AppliChem, Darmstadt 
Sodium hydroxide Riedel-de Haen, Seelze 
Sodium pyruvate Merck, Darmstadt 
Sodium thiosulphate Merck, Darmstadt 
Tris Roth, Karlsruhe 
Triton-X-100 Sigma, Steinheim 
Trypan bue Serva, Heidelberg 
Trypsin Sigma, Steinheim 
Trypton AppliChem, Darmstadt 
Tween 20 Serva, Heidelberg 












10mM HEPES pH7.4, 140nM NaCl, 25mM CaCl2 
Bicarbonate buffer 
pH 9.6 
15mM Na2CO3, 35mM NaHCO3. Fill to 900ml with distilled 
water. Adjust pH to 9.6 and make it upto 1l with water. 
Blot buffer (5x) 10g SDS, 142g Glycine, 30.3g Tris base and make upto 1l 
with distilled water. 1X buffer was made fresh by taking 5x 
Blot buffer, methanol and distilled water in the ratio 1:1:3 
DEPC water 200たl DEPC reagent in 1l distilled water and autoclave 
Ethidium Bromide 0.2g Ethidium bromide, distilled water 20ml. Stored in 
dark. 
Freezing medium 90%FCS, 10%DMSO 
Glycine solution 0.2M glycine in PBS 
HEPES buffer 25mM HEPES pH7.2, 150mM NaCl, 5mM MgCl2, 1mM 
PMSF, 1x Protease inhibitor, 1mM NaVO4, detergent as 
indicated in experiments 
LB medium 10g Peptone, 5g Yeast extract, 10g NaCl, fill upto 1l with 
Distilled water. For LB plates 15g agar was added. 
PBS (pH7.2) 137mM NaCl, 2.7KCl, 4.3mM Na2HPO4 in distilled water 
Running buffer for 
protein gels (10x) 
 10g SDS, 144g Glycine, 30g Tris, filled upto 1l with 
distilled water 
TAE Buffer 242g Tris base, 57.1ml Glacial acetic acid, 100ml 0.5m 
EDTA pH 8.0, Add distilled water 1l and adjust final pH to 
8.5.  
TNES buffer 50mM Tris, 0.4M NaCl, 100mM EDTA, 1% SDS. 
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2.2   Methods: 
2.2.1 Molecular biology 
 
2.2.1.1 Chemical Competent cells : 
From a 50 ml DH5c overnight culture, 1 litre of LB medium (NO  ANTIBIOTIC) 
was cultivated till the O.D.600nm  reaches 0.5-0.6.  Cells were then centrifuged 
in the Sorvall GSA rotor (250 ml centrifuge bottle) at 5,000 RPM for 10 minutes 
at 4oC, bacteria pellet was gently resuspended in 1/4 volume of ice cold sterile 
Magnesium chloride (MgCl2).  Cells were again centrifuged 4000 RPM in the 
Sorvall GSA rotor for 10 minutes and bacterial pellet was now re-suspended in 
1/20 volume of ice cold Calcium chloride (CaCl2). Cells were centrifuged 4,000 
RPM in the GSA rotor for 10 minutes and the cell pellet was re-suspended in 
1/50 volume of ice cold, sterile  85 mM CaCl2 in 15% glycerol w/v. cells were 
aliquoted  in 50 µl each and stored  at -80oC. 
2.2.1.2 Transformation:  
Competent cells were thawed on ice and 1-10ng of plasmid was added and 
kept on ice for 30 mins. Competent cell plus plasmid was given a heat shock at 
42°C for 2 mins and kept on ice for another 5 mins. To this 1 ml of LB medium 
was added and kept at shaker for 1 hr at 37°C. 10 to 100 µl was then plated on 
LB agar plate containing selection drug (ampicilline at 100µg/ml). Plates were 
incubated overnight at 37°C. 
2.2.1.3 Mini-Prep: 
Single colonies were recovered from LB agar plates in 2 ml LB medium 
containing selection agent (ampicilline at 100µg/ml) on a shaker set at 200 rpm 
at 37°C. overnight. 1ml bacterial suspension was used for miniprep following 
producers recommendations (Miniprep kit, Qiagen). Positive clones were 




2.2.1.4 Enzymatic restriction digestion: 
For double digestion 1 µg purified plasmid with insert was mixed with 0.5µl (5U) 
primary restriction enzyme and appropriate digestion buffer (1x).Total volume 
was completed with distilled water to 10 µl and digestion was performed 1-2 hr 
in a water bath at 37°C. After digestion, DNA was purified over Qiagen mini-
column and a second enzymatic digestion was performed following the same 
procedure. Samples containing right sized fragments were then proceeded via 
midiprep for transfection. 
2.2.1.5 Midi-Prep 
To obtain sufficient amount of vector DNA necessary for transfection, overnight 
cultures of positive clones were incubated overnight on shaker set at 200 rpm 
at 37°C in 100ml of LB medium containing appropriate selection antibiotic 
(ampicilline at 100µg/ml) whole bacterial culture was used for midi-prepration 
following producers recommadations (Midi-prep Kit,Qiagen). 
2.2.1.6 RNA preparation, cDNA synthesis and amplification 
Total RNA isolation was done from 107 cells with Tri reagent following 
manufacturers instructions (Applichem, Darmstadt, Germany). Quality of RNA 
preparation was checked by running RNA sample diluted in RNA sample buffer 
on 1% agarose/formaldehyde gel. 
cDNA synthesis and amplification was performed by RTPCR (reverse 
transcriptase polymerase reaction). 1-2 たg template RNA was mixed with 0.5たg 
oligo dT primer and heated at 70°C, 5 min; chilled on ice, then mixed with 1たl 
Im Prom II reverse transcriptase (10U), 1-2mM dNTP, 1x Im Prom II buffer 5x, 
6mM MgCl2 and made upto a total of 20たl with nuclease free water.The 
program continues as 25°C-5min, 42°C-60min and 70°C-15min. 
PCR was performed in 25 たl volume containing template, 1-2 mM dNTP, 1.5たl 
Red Taq polymerase, 2.5 たl 10x Taq buffer and 0.2 たM primer forward and 




CD44s : 94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32cycles, 72°C-
10min 
CD44v3 : 94°C-5min, 94°C-30secs, 54°C-30secs, 72°C-1min, 32cycles, 72°C-
10min 
CD44v6 : 94°C-5min, 94°C-30secs, 53°C-30secs, 72°C-1min -32 cycles, 72°C-
10min 
CD44v7 : 94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32 cycles, 72°C-
10min 
CD44v8 : 94°C-5min, 94°C-30secs, 54°C-30secs, 72°C-1min, 32cycles, 72°C-
10min 
CD44v9 : 94°C-5min, 94°C-30secs, 53°C-30secs, 72°C-1min -32 cycles, 72°C-
10min 
CD44v10 : 94°C-5min, 94°C-30secs, 53.5°C-30secs, 72°C-1min -32 cycles, 
72°C-10min 
GAPDH : 94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32 cycles, 72°C-
10min 
2.2.1.7 DNA gel electrophoresis 
PCR products or samples containing DNA of interest were checked by running 
an agarose gel of 1 to 2%, depending on the size of the product. When Red 
Taq polymerase was not used then DNA sample was mixed with DNA loading 
dye (6x) to locate the running front. Markers (1kb or 100bp) were run in parallel. 
The gel was run at 100 volts in a migration tank containing 1x TAE buffer. 




2.2.2 Protein Chemistry 
2.2.2.1 Antibody purification  
Antibody purification was done by affinity chromatography using a sepharose 
protein G-4B column. To purify IgG fractions, sterile filtered hybridomas 
supernatants were  passed over a sepharose protein G-4B column. The column 
was washed with 0.1M phosphate buffer, pH 7.5. Bound IgG was eluted from 
the column with 0.1M Glycine buffer pH 2.7. Protein containing fractions were 
dialyzed against PBS, concentrated and filter-sterilized. The protein amounts 
obtained were photometrically analysed for protein concentration by Biorad 
assay. 
2.2.2.2 Column preparation (CNBr coupling) 
10mg purified anti-myc antibody (9e10 hybridoma) were covalently coupled to 
CNBr activated sepharose. For this purpose, CNBr coupling method was used 
as follows: After purification over a protein-G-sepharose 4B column, 
concentration and dialysis against PBS, the anti-myc antibody was further 
dialysed overnight against  carbonate coupling buffer pH8.3 at 4°C and 
adjusted thereafter to 6 mg/ml in coupling buffer; 0.5g CNBr activated 
sepharose were swollen in 1mM HCl solution. Thereafter the gel was washed 
with 5ml coupling buffer and sucked off until cracks appeared in the cake. Gel 
was then immediately transferred to 15 ml tube containing the antibody solution 
and incubated under agitation overnight at 4°C. Beads were then spun down 
(2,000 rpm, 1min) and efficiency of the coupling procedure was measured, by 
quantifying the amount of protein remaining in the supernanant; Biorad reagent 
was used for this purpose. OD was read at 565nm. If OD was 10 fold lower 
comparing to starting ligand solution, coupled beads were further washed 3 
times with 10 column volumes coupling buffer, incubated 2 hours at room 
temperature in 10 ml filtered blocking solution 0.2M glycine pH8.0 and then 
washed 4 times alternatively with wash buffer pH4.7 and coupling buffer pH8.3. 
OD 595nm was read at first and fourth wash. The gel was poured into 
chromatography column and washed with 5 volumes columns PBS-azide 
0.01%pH7.3 and stored at 4°C until use.  
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2.2.2.3 Purification of the CD44 recombinant soluble protein 
To purify the soluble molecules, the HEK293- EBNA1 transfectant supernanat 
were cleared by centrifugation15min at 3,000 rpm and sterile filtered. Filterate 
was supplemented with 0.05% Natrium azide and passed over anti-myc affinity 
column at 0.3ml/min over 24 hours. Elution was done using a 0.2M glycine 
pH2.7 buffer. Eluted fractions were collected in 1:20 volume 1M Tris buffer 
pH8.0 then concentrated and dialyzed against cold PBS using Vivaspin tubes 
(50 Kda cut off). Protein concentration was measured by Biorad assay. 
2.2.2.4 Biorad assay 
This test is based on the affinity of the  coomassie dye G-250 for proteins. In 
microassay it allows detections of BSA amounts under 25µg/ml. To proceed 
with detection of the soluble proteins, 1µl of each sample to test were diluted in 
a flat micotiter well with 99µl Biorad reagent prediluted (1 :10 in distilled water). 
In parallel, a 10mg/ml BSA solution in water was serially diluted to allow 
drawing of a standard curve. After 5min incubations, optical densities were read 
at 595nm on an ELISA reader. Optical densities were reported to the standard 
curve for concentration calculation. 
2.2.2.5 Pulldown assay 
Cell lysates were passed over the soluble CD44s and soluble CD44v7 
sepharose column. Column was washed with PBS and finally Elution was done 
using a 0.2M glycine pH2.7 buffer. Eluted fractions were collected in 1:20 
volume 1M Tris buffer pH8.0 then concentrated and dialyzed against cold PBS 
using Vivaspin tubes (50 Kda cut off). Protein concentration was measured by 






2.2.2.6 SDS- polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein components were separated using SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). SDS, an anionic detergent denatures and 
imparts negative charge to all proteins in the sample. Proteins can be 
separated according to their size in an electrical field.  Two gels were used for 
this purpose. At the bottom resolving gel was poured to separate the proteins 
and at the top a stacking gel. The stacking gel concentrates all proteins in one 
band and allows them to enter the resolving gel at the same time; it can be 
mounted with a comb to load samples in the wells.  Before loading the gel, 
samples were boiled for 5 minutes at 95° C for proteins to allow complete 
protein denaturation. Around 25-30 たl of sample was loaded into wells. The 
inner and outer chambers were filled with running buffer (1x). 
2.2.2.7 Immunoprecipitaion 
Freshly harvested cells from bone marrow or cultured cells (107) washed 3 
times in cold PBS were lysed in 1ml HEPES buffer containing protease inhibitor 
and phosphate inhibitors as well as detergent (mainly 1% Lubrol) for 1 hour at  
4°C on a rocking platform.  Lysates were then centrifuged 10min at 13,000 rpm, 
4°C. Lysed supernatants were collected. Immunoprecipitation was done using 
1 to 5 µg specific monoclonal or polyclonal antibodies at 4°C on a rocking 
platform for over night. Following over night incubation at 4°C, 5% of protein G-
sepharose was added to the precleared lysates for 1 hour. Protein G coupled 
antibody was washed 3 times with lysis buffer completed with detergent. 
Sepharose pellet was resuspended in 80たl Laemmli buffer and boiled 5min at 
95°C. After 1min centrifugation at maximum speed, 20たl of the supernatant 
were taken and load on acrylamide gel to be resolved by SDS-PAGE. If 
indicated, cells were biotinylated before lysis and immunoprecipitation. Washed 
cells were resuspended in HEPES buffer containing 0.1mg/ml NHS-water 
soluble biotin. Biotinylation was performed 30min under agitation at 4°C. 
Reaction was terminated by 3 washes with 0.2M glycine PBS solution. Cells 
were lysed 1 hour at 4°C in 1ml HEPES buffer containing protease and 
phosphatases inhibitors as well as detergent of choice. Following steps were 
similar as described above. 
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2.2.2.8 Western Blotting  
Following gel electrophoresis proteins were electroblotted onto a nitrocellulose 
membrane (Amersham Biosciences) overnight at 30 volts and analysed by 
immunoblotting using specific primary and secondary antibodies. The gel, foam 
pads and 3MM Whattmann papers were equilibrated in blotting buffer; the gel 
was placed on the membrane which in turn was placed on Whattmann paper 
followed by foam pads on either side. The whole set was placed in a cassette 
holder, followed by a tank blotting apparatus such that the membrane was 
placed towards the anode side. After overnight transfer the blots were blocked 
with PBS/5% Milk powder or BSA (for phosphospecific antibodies) for 1 hour, 
followed by primary antibody for 1 hour. Blots were washed with 
PBS/0.1%Tween thrice and 5 minutes each wash. Then the blots were 
incubated in secondary antibody for an hour, followed by washing again. The 
blots were developed with Enhanced Chemiluminescence system (ECL, 
Amersham Biosciences) and exposed to X-ray film (Amersham Biosciences) for 
desired time points and developed.  
 2.2.2.9 Silver staining of protein gels 
After separation of proteins by SDS-PAGE, gels were fixed overnight in 30% 
ethanol/10% acetic acid and sensitized for 45min in 0.3% potassium 
tetrathionate, 0.5M potassium acetate, 30% ethanol. This was followed by 6 
washes, totally for 1h with bidest water. Gels were stained with 0.2% silver 
nitrate for 1-2hr, rinsed with bidest water and developed for upto 40min in 
developer (3% potassium carbonate, 31µl Na2S2O3-5H2O (10%), 75µl formalin 
(37%) per 250ml). The reaction was stopped by adding 330mM Tris/ 2% acetic 
acid and gels were kept in bidest water. 
2.2.3 Cell biology 
2.2.3.1 Cell culture 
Cells were grown in a humidified incubator at 37°C, 5% CO2. Cells were 
maintained in RPMI or ISCOVEs medium in 10% FCS as per the requirements 
and split when they reached confluency. Cells were usually passaged at a ratio 
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of 1:4. Trypsin (0.25%) (w/v) in PBS was used to disperse adherent cells and 
reseeded to fresh culture flasks. 
For long term cell storage, cells were washed once with medium and frozen in 
cryovials in FCS, 10% DMSO. The vials were placed for 1 hour at -80°C before 
transferring into liquid nitrogen. Cells were thawed from the cryovials by placing 
the vials from liquid nitrogen first on ice, followed by 37°C water bath and 
immediately placed in falcon containing medium and centrifuged at 1600 rpm 
for 5 minutes. The medium was sucked off and new medium was added and 
transferred to flasks at high density to maximise recovery. 
Cell viability was determined using hemacytometer and trypan blue staining. 
Tryptan blue (2x): 0.4% Trypan blue (4vol) 
                                4.5% NaCl (1vol) 
 
2.2.3.2 Magnetic Beads separation 
Bone marrow cells (BMC) were stepwise depleted of CD4+, CD8+ and NK cells, 
CD19+, CD45+, CD11c+ and CD11b+, Ter119+ and Ly6C/G+ cells by magnetic 
beads coated with the respective antibodies (Miltenyi Biotec, Bergisch 
Gladbach, Germany). The depleted cells population was incubated with anti-
CD117-coated beads collecting the adherent fraction. The CD117+ cells mostly 
were further enriched for HSC by incubation with biotinylated anti-SCA1 and 
anti-biotin coated beads, again collecting the adherent population. The regain 
of CD117+ cells varied between 2.6% to 5.3%. In BALB/C mice, roughly 30% of 
CD117+ cells were SCA1+, in SVEV the recovery of SCA1+ cells from CD117+ 






2.2.3.3 Flow cytometry 
Fluorescent activated cell sorting (FACS) allows cell segregation based on size 
and volume and also allows detecting expression levels of proteins in cells. 
This method is based on diffraction of light and measure of fluorescence which 
reflects cell size and amount of fluorescent antibody labelled cells. 
Cells were washed in PBS/0.5% BSA. About 5x105 cells were added to round 
bottomed 96 well plates. After centrifugation cells were suspended in 50 たl of 
primary antibody diluted in PBS/0.5% BSA and incubated for half an hour on 
ice. This was followed by washing the cells thrice with PBS/0.5%BSA, 5min 
each wash. Secondary antibody (50たl) coupled to fluorochrome was added to 
each well and incubated for half an hour on ice in the dark. The cells were 
again washed. After the last wash cells were suspended in 200たl    
PBS/0.5%BSA for immediate measuring. Staining was evaluated using FACS-
Calibur (Becton Dickinson, Heidelberg, Germany).  In case of double or triple 
fluorescence the same procedure was repeated with adequate antibodies and 
blocking steps wherever necessary (e.g. different antibodies form the same 
species). 
For cytokines, intracellular FACS was performed. The cells were first incubated 
with formalin 1% to fix them for 20 minutes on ice. The cells were washed with 
PBS 1%BSA 3x as mentioned above. Thereafter the cells were incubated with 
0.1 % Tween for 15 minutes on ice to create pores on the cell membrane and 
facilitate the entry of antibodies against the cytokines into the cells. The cells 
were again washed and antibodies were added following the usual protocol. 
Mitochondrial integrity was determined by DilC1 staining, measuring 
fluorescence in the FL4 channel. The cell cycle was controlled by PI staining 
(1たg/ml, 0.1% TritonX-100, RNAase A) after fixation in ethanol. Samples were 





2.2.3.4 Apoptosis Assay 
Apoptosis assay was performed using Annexin V-FITC and propidium iodide 
(PI) (R & D systems, Wiesbaden-Nordenstadt, Germany) double staining. Early 
apoptotic cells bind to Annexin V because of the exposed phosphatidylserine 
on the outer cell membrane. Late apoptotic cells are positive for Annexin V and 
PI. Necrotic cells bind only PI. BMC and HSC were seeded on plastic, HA or 
LTBMC-stroma for 24 hour and 48 hour in the presence or absence of 5µg/ml 
cisplatin. After the desired time points cells were transferred to 96 well plates 
and plates were centrifuged at 1600 rpm for 5 minutes and washed with 
PBS/1% BSA. Cell labelling was performed according to manufacturers 
instructions. Cell were incubated in the dark at RT for 15 min and detected by 
FACS using the FL1 channel for Annexin FITC and FL-3 channel for PI. 
2.2.3.5 Proliferation 
BMC and HSC were labelled with CFSE and cells were seeded on plastic or 
HA or on LTBMC-stroma. To check for the proliferative activity, cells were 
evaluated for 72 hour in the presence or absence of anti-CD44 or anti-CD49d. 
Cell division was evaluated by CFSE dilution and detected by FACS using FL1 
channel. To label the cells with CFSE, cells were washed with PBS 2 times and 
2-3 µg/ml CFSE (pre diluted in PBS) was added to the cells. Cells were 
incubated at 37°C for 30min. To quench the reaction, 1 volume cold FCS was 
added to the cells. Cells were washed with RPMI medium 2 times and cells 
were resuspended in RPMI medium and kept at 37°C for 20min. After 
incubation,  cells could be used for the seeding for different time points. 
2.2.3.6 Phosphatase assay  
Cell lysates, centrifuged at 12,000g for 10min, were incubated with anti-PP2A 
and ProteinG-agarose (Roche, Mannheim, Germany) (2h, 4°C). The 
immunoprecipitate was washed and incubated with 900たg/ml p-NPP (30min, 
37°C). The amount of para-nitrophenol produced by dephosphorylation was 
determined by measuring the absorbance at 405nm. 
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2.2.3.7 Sucrose gradient centrifugation 
Cells were lysed in 1% Lubrol, lysates were centrifuged (10min, 20,000g), 
adjusted to 40% sucrose (4.5ml) and were layered on 1.3ml of 50% sucrose 
and overlaid with 2.3ml of 30%, 2.3ml of 20%, and 1.3ml of 5% sucrose. After 
centrifugation (200,000g, 16h), 12 fractions (1ml) were collected from the top of 
the tubes. Fractions 1-4, 5-8 and 9-12 were pooled and precipitated with anti-
CD44. 
2.2.3.8 Cytosol, nuclei and mitochondria preparation 
Cells were incubated in hypotonic buffer, homogenized and centrifuged at 
800rpm for pelleting the nuclei. For separating the cytosolic from the 
mitochondrial fraction, 2.5x106 cells were lysed in 0.5ml lysis buffer. After 
adding Nonidet-P40 (0.5%), vortexing, and centrifugation (1600rpm, 5min), 
cytosolic proteins are recovered from the supernatant. The pellet (mitochondria) 
and the pelleted nuclei were washed, resuspended in lysis buffer (1% TritonX-
100, 1% SDS) and sonicated (7sec, 9cycles). 
 
2.2.3.9 Transfection of adherent cells 
HEK-293 EBNA cells were transfected using Polyfect reagent from Qiagen 
following manufacturers instructions. Briefly, 2µg pCEP-puromycin modified 
vector were diluted in 0.1ml ISCOVEs (without serum and antibodies) with 20µl 
Polyfect and incubated 10 min at room temperature. Meanwhile, cells at 40-
80% confluency in a 6-well-plate were given 1.5ml fresh complete ISCOVEs 
10% FCS, 2mM L-glutamine, 250µg/ml neomycin per well. After 10min, 0.6ml 
complete medium was added to the DNA solution and distributed 
homogeneously on cells; the plate was rocked gently to assure equal 
distribution of DNA on the well, and then transferred to 37°C, 5% CO2 culture 
conditions. After 24hr culture, cells were passed in a 75cm2 flask and 24hr later 
puromycin selection was done with 0.5µg/ml. Cells were tested 2 weeks later 
for soluble molecule presence in the supernatant by western-blot. 
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2.2.4 Animal experiments  
2.2.4.1 Long term bone marrow culture (LTBMC) 
Bone marrow cells (BMC) were collected from femur and tibiae of 6-10 weeks 
old mice by flushing the bones with PBS through a 27 gauge needle. Cells were 
washed and seeded at a density of 2 X 106 cells / ml in ISCOVEs Minimal 
essential medium supplemented with 20% horse serum (HS), 25µm 2-ME (2-
Mercapto Ethanol), 2mM L-glutamine and 10 µm Hydrocortisone. Medium was 
exchanged very carefully weekly. After 6 week of culture, the monolayer of 
adherent stroma cells (LTBMC-stroma) was used for further analysis. 
 
2.2.4.2 Reconstitution and tumor cell injection 
C57BL6 mice received an i.v. or s.c. injection of 104 EL4 cells or were lethally 
irradiated (9.5Gy) and reconstituted with 1x107 T cell-depleted BMC and 
received EL4 cells 2days after reconstitution. Both groups of mice received 
twice per week an i.v. injection of 150たg control IgG or anti-panCD44 (IM7). 
Survival time and reconstitution were controlled. In a second setting, C57BL6 
mice were treated as described above, but received 2x106 CFSE-labeled EL4 
cells. The % of CFSE-labeled EL4 cells and of apoptotic (AnnexinV-APC 
stained) CFSE-labeled EL4 cells in bone marrow, thymus and spleen was 
evaluated during 96hrs. Animal experimentations were approved by the 
governmental authorities of Baden-Wuerttemberg, Germany.  
2.2.5 Statistical analysis 
Significance of differences was calculated according to the Student's T test (in 
vitro studies). Functional assays were repeated at least 3 times. Mean±SD of in 







Part I: The importance of CD44 in the crosstalk between HSC 
and bone marrow stroma  
 
1. CD44 expression, associating molecules and ligands on HSC and 
niche cells 
CD44 has been demonstrated to be required for HSC maintenance as well as 
their retention in the osteoblastic niche. It is largely unknown whether 
expression of CD44s or CD44v is required on HSC or the cells of the 
osteogenic niche. To answer these questions, I characterized bone marrow 
cells and as a surrogate for the osteogenic niche long term bone marrow 
culture stroma and S17 cells, a murine stromal cell line. 
 
1.1 CD44 expression on BMC and LTBMC-stroma cells 
HSC are a small subpopulation of BMC. To characterize this small 
subpopulation, it was essential to separate it from committed progenitors and 
mature leukocytes in the bone marrow. This has been achieved by selection 
with antibody coated magnetic beads. The efficacy of separation was controlled 
by flow cytometry, which evaluated several stem cells, progenitors and mature 

















Figure 1A: Expression of stem cells, progenitors and mature leukocyte marker in BMC/HSC. 
Unseparated and separated populations of Bone marrow cells (BMC) including Hematopoietic stem cells 
(HSC) were analyzed for HSC, Progenitor and Mature leukocyte markers by flow cytometry. 
These stem cells, progenitor and mature leukocyte markers were known to be 
expressed on mature progenitor cells in the hematopoietic lineage. CD117 and 
SCA-1 (E13 antibody) are known markers for HSC population and in Fig.1A 
expression of these markers was high in HSC. Progenitor cell markers i.e. 
CD90 (Thy-1), Ter119, Ly6 (hematopoietic marker), CD38 and Gr-1 
(granulocyte marker) were highly expressed in unseparated BMC. Mature 
leukocyte markers CD16 (found on NK cells), CD24 (expressed on 
granulocytes and B cells), CD71 (expressed on activated T and B lymphocytes, 
macrophages) and CD43 (leukocyte marker)   were expressed in high levels in 
BMC as well as in HSC while CD81 (leukocyte marker) was found to be high 






































































































Figure 1B: Expression of stem cells, progenitors and mature leukocyte marker in LTBMC- stroma. 
Long term bone marrow culture stroma (LTBMC-stroma) were analyzed for HSC, Progenitor and Mature 
leukocyte markers by flow cytometry. 
Same markers were checked on LTBMC-stroma and expression of CD16 and 
CD71 was found to be high (Fig. 1B). 
Next, I characterized CD44 and CD44 variant isoforms on BMC sub 






















































































































Figure 1C: Expression of CD44 and CD44v in BMC sub populations. Unseparated and separated 
populations of Bone marrow cells (BMC) including Hematopoietic stem cells (HSC) were analyzed for 
CD44 and CD44v expression by flow cytometry. 
A flow cytometry analysis for CD44s, CD44v3, CD44v6, CD44v7 and CD44v10 
on bone marrow cells (BMC), mature leukocytes within the bone marrow, 
committed progenitors of the erythroid and myeloid lineages, CD117+/SCA1- 
and CD117+/SCA1+ HSC showed high expression for CD44 while CD44v7, 
CD44v10 and CD44v6 were mainly expressed by HSC and committed 









Figure 1D: Expression of CD44 and CD44v in LTBMC-stroma and S17 cells. Long term bone marrow 
culture-stroma cells (LTBMC-stroma) and S17 cells (murine stromal cell line) were analyzed for CD44 and 
CD44v expression by flow cytometry. 
Expression of CD44s, CD44v3, CD44v6, CD44v7 and CD44v10 was checked 
on LTBMC-stroma and S17 cells, which were taken as surrogate niche cells. 
CD44s was highly expressed in both while CD44v6 was expressed by S17 cells 




























A semi-quantitative RT-PCR analysis of unseparated bone marrow and 
LTBMC-stroma revealed that in bone marrow CD44s, CD44v7 and CD44v10 
were highly expressed and also revealed that CD44v8 and CD44v9 were 
always come together with CD44v10 isoforms. In LTBMC-stroma CD44v7 was 
highly expressed but CD44v3 and CD44v6 showed low expression, which was 
found to be very weak in the bone marrow. CD44v8 and CD44v9 showed 
expression in combination with CD44v10 (Fig. 1E).  
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Figure 1E: RT-PCR for BM and LTBMC-Stroma: cDNA was prepared from bone marrow cells (BMC) 
and long term bone marrow culture-stroma (LTBMC-stroma) and semiquantitative RT-PCR was made 
under specific conditions.  
Lane 1:  Marker 100bp.  
Lane 2,3,4,5,6,7,8: CD44s, CD44v3, CD44v6, CD44v7, CD44v8, CD44v9 and CD44v10 respectively. 
1.1.1 RT-PCR profiling on BMC subpopulations 
A semiquantitative RT-PCR analysis of mature leukocytes within the bone 
marrow, committed progenitors of the erythroid and myeloid lineage and 
CD117+/SCA1+ cells (HSC) revealed that HSC mostly express CD44v7 and 
CD44v10 while mature committed progenitors showed CD44v10 and CD44v10 
combined with all other isoforms (Fig. 1F).  
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Figure 1F: RT-PCR of separated BMC subpopulations: cDNA was prepared for indicated 
subpopulations and semiquantitative RT-PCR was made under specific conditions.  
Lane 1: Marker 100bp 
Lane 2,3,4,5,6,7,8: CD44s, CD44v3, CD44v6, CD44v7, CD44v8, CD44v9 and CD44v10 respectively. 
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1.1.2 Adhesion molecule profile in BMC and LTBMC-stroma cells 
CD44 has been described to be essential for the interaction between HSC and 
their niche. Yet other adhesion molecules have also been described to be 
involved. Furthermore, besides binding to HA, CD44 also binds to specific 
ligands and can associate with integrins or cell adhesion molecules. Therefore 



























Figure 1G: Integrin expression profile on BMC, HSC and LTBMC-stroma cell. Unseparated bone 
marrow cells (BMC), hematopoietic stem cells (HSC) and long term bone marrow culture (LTBMC-stroma) 


























Figure 1H: Expression of cell adhesion molecule and selectins on BMC, HSC and LTBMC-stroma 
cell. Unseparated bone marrow cells (BMC), hematopoietic stem cells (HSC) and long term bone marrow 
culture (LTBMC-stroma) were analyzed for cell adhesion molecules and selectins by flow cytometry. 
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CD18 (Leukocyte marker), CD49d (alpha-4 integrin, essential to the 
differentiation and traffic of hematopoietic stem cells) and CD49e were highly 
expressed on BMC and HSC. CD11b (monocytic marker), CD49d and CD49e 
were found on LTBMC-Stroma cells. ICAM molecule CD54 was predominantly 
expressed in BMC, HSC and LTBMC-stroma (Fig. 1G & 1H).  
1.1.3 Cytokines and cytokine/chemokine receptor expression on BMC and 
bone marrow stroma cells 
Cytokines are a broad family of proteins that mediate HSC mobilization and 
homing. In BMC and HSC transendothelial trafficking is dependent on the 
expression of adhesion molecules, which is induced by different cytokines and 
chemokines and their receptors. Therefore, cytokines and cytokine receptor 
expression was evaluated by flow cytometry. IL-3 and IL-7 stimulates the 
differentiation of HSC into mature progenitors and SDF-1 is a known ligand for 
chemokine receptor, CD184 (stromal cell-derived factor-1 receptor) which was 
found to be very high in BMC, HSC and LTBMC-stroma. GMCSF, IL3, IL7 and 


























Figure 1I: Cytokines and cytokines receptors expression on BMC, HSC and LTBMC-stroma cells. 
Unseparated bone marrow cells (BMC), hematopoietic stem cells (HSC) and long term bone marrow 
culture (LTBMC-stroma) were analyzed for cytokines and cytokine receptors by flow cytometry. 
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These data showed that HSC and LTBMC-stroma share high expression of 
CD44. HSC differed from LTBMC-stroma in CD44 variant expression. HSC 
mostly expressed CD44v7 and CD44v10. LTBMC-stroma predominantly 
expressed CD44v7, mature leukocyte marker CD16 and CD71. Additional 
adhesion molecule like CD102 (ICAM-2, intercellular cell adhesion molecule-2), 
CD49e integrin were found in HSC and LTBMC-stroma as well. 
Most prominent markers CD49d and CD54 were found on HSC and LTBMC-
stroma cells. Similarly the chemokine receptor marker CD184 was 
predominantly expressed in BMC/HSC and LTBMC-stroma. 
 
1.2 CD44 associating molecule in HSC and bone marrow stroma cells 
 
1.2.1 CD44 co-expression with stem cell, progenitor cell and mature 
leukocyte markers on BMC/HSC and LTBMC-stroma cells 
CD44 has been demonstrated to be essential for the interaction between HSC 
and their niche. Therefore, it became important to analyze the co-expression of 
CD44 with stem cell, progenitor cell and mature leukocyte markers on 
BMC/HSC and LTBMC-stroma.   
Double fluorescence staining provided evidence that CD44 is co-expressed 
with different stem cells, progenitor and mature leukocyte markers on BMC. In 
BMC, CD44v6 and CD44v7 showed co-expression with leukocyte markers 
CD43 and CD81 (expressed on hematopoietic cells). They were also co-
expressed with progenitor and stem cell markers, Gr-1 (granulocyte marker) 
and CD117. CD44v10 was co-expressed with majority of stem cell, progenitor 


























Figure 2A: CD44 co-expression with stem cells, progenitors and mature leukocyte markers on 
bone marrow cells (BMC). Bone marrow cells were double stained with anti-CD44v6, anti-CD44v7 and 
anti-CD44v10 and the indicated markers. The percentage of CD44+marker-, CD44+marker+ and CD44-




























































































































































































































































Figure 2B: CD44 co-expression with stem cells, progenitors and mature leukocyte markers on long 
term bone marrow culture stroma (LTBMC-stroma). Long term bone marrow culture-stroma cells 
(LTBMC-stroma) were double stained with anti-CD44v6, anti-CD44v7 and anti-CD44v10 and the indicated 
markers. The percentage of CD44+marker-, CD44+marker+ and CD44-marker+ cells was shown. 
CD44 also co-expressed with different markers in LTBMC-stroma. CD44v6, 
CD44v7 and CD44v10 were co-expressed with CD16 and CD71, but partly with 























































































































































































































































1.2.2 CD44 co-expression with cytokine/chemokine receptors on 
BMC/HSC and long term bone marrow-stroma cells 
As outlined above the chemokine receptors CD184 and cytokines IL-3 and IL-7 
are supposed to mediate differentiation and proliferation of HSC. CD184 might 
promote homing of HSC into bone marrow niche and also mediates chemotaxis 
in mature and progenitor blood cells and, together with its ligand SDF-1, is 
essential for B lympho- and myelopoiesis. Therefore, I checked co-expression 
of CD44 with cytokine and chemokine receptors. CD44v6, CD44v7 and 
CD44v10 showed co-expression with CD184 (SDF-1 receptor) chemokine 
receptor on bone marrow cells. CD44v10 is also co-expressed with CD123 (IL3 














Figure 2C: CD44 co-expression with cytokine/chemokine receptors on bone marrow cells (BMC). 
Bone marrow cells were double stained with anti-CD44v6, anti-CD44v7 and anti-CD44v10 and cytokine 
and chemokine receptor markers. The percentage of CD44+marker-, CD44+marker+ and CD44-marker+ 



















































































Figure 2D: CD44 co-expression with cytokine/chemokine receptors on long term bone marrow 
culture (LTBMC-stroma). Long term bone marrow cells were double stained with anti-CD44v6, anti-
CD44v7 and anti-CD44v10 and cytokine and chemokine receptor markers. The percentage of 
























































































1.2.3 CD44 co-expression with adhesion molecules on BMC/HSC and 
bone marrow stroma cells 
The adhesion molecules are involved in the cellular interactions between HSC, 
LTBMC-stroma cells and BMC to regulate hematopoiesis and mediate 
mobilization and homing of HSC. Therefore, it became important to evaluate 
the co-expression of CD44 with adhesion molecules. In BMC, CD44v6 was co-
expressed with CD49d, CD49e, CD51 (expressed on megakaryocyte and 
platelets), CD61, CD11b, CD11c (dendritic cell marker), CD62L (L-selectin) and 
CD62P (P-selectin). CD44v7 was co-expressed with CD49d, CD49e, CD54 and 
CD62L. CD44v10 was co-expressed mainly with CD51, CD61, CD49d, CD49e, 














Figure 2E: CD44 co-expression with adhesion molecules on bone marrow cells (BMC). Bone 
marrow cells were double stained with anti-CD44v6, anti-CD44v7 and anti-CD44v10 and the indicated 



















































































































































































































































































In LTBMC-stroma CD44v6, CD44v7 and CD44v10 were co-expressed with the 
integrins CD11b, CD49d, CD49e and CD54 but only partly with CD11c, CD51 















Figure 2F: CD44 co-expression with adhesion molecules on LTBMC-stroma cells. Long term bone 
marrow culture-stroma cells (LTBMC-stroma) were double stained with anti-CD44v6, anti-CD44v7 and 
anti-CD44v10 and the indicated markers. The percentage of CD44+marker-, CD44+marker+ and CD44-











































































































































































































































































































1.2.4 CD44 associating molecules on BM, HSC and LTBMC-stroma cells 
Co-localization does not imply an association of the neighbouring molecules. 
Thus, it became important to see, which of the co-localizing molecules actually 
interact with CD44. To answer the question, I performed co-
immunoprecipitation analysis.  
Co-immunoprecipitation studies revealed a direct association of CD44 with 
CD49d and CD54 in BMC, HSC and LTBMC-stroma cells (Fig. 2G & 2H). 
 
 
Figure 2G: CD44 associating molecules on BMC: Biotinylated bone marrow cells (BMC) lysate  was 
immunoprecipitated with IM7 and precipitates were dissolved by SDS-PAGE. After transfer proteins were 
detected by streptavidin-HRP or the indicated antibodies. CD44, CD49d, CD54, CD44v7 indicated 
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Figure 2H: CD44 associating molecules on BMC, subpopulations and LTBMC-stroma : Bone 
marrow cells (BMC), hematopoietic stem cells (HSC) and long term bone marrow culture-stroma (LTBMC-
stroma) lysates were immunoprecipitated with IM7 and anti-CD44v7, precipitates were dissolved by SDS-
PAGE. After transfer associated proteins were detected with indicated antibodies. 
  
                                                                                
 
Figure 2I: CD44 associating molecules on LTBMC-stroma: Biotinylated long term bone marrow 
culture-stroma (LTBMC-stroma) lysate was immunoprecipitated with IM7 and anti-CD44v7 and 
CD54CD49dCD44v7
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precipitates were dissolved by SDS-PAGE. After transfer proteins were detected by streptavidin-HRP. 
CD44, CD49d, CD54, CD44v7 indicated molecular weight 80kD, 150kD, 95kD, 100kD respectively.      
In HSC and LTBMC-stroma CD44, pre-dominantly CD44v7 were associated 
with CD49d and CD54. Additional associating molecules are expected to be 
identified by MALDI-TOF. 
 
1.3 Potential ligands of HSC and stroma cells for CD44 and CD44v  
As mentioned, a blockade of CD44 does not only prevent HSC homing, but 
also can drive HSC into apoptosis and differentiation. Accordingly, it is 
expected and there is strong evidence that signal transduction is initiated by 
CD44 ligand binding. Thus, besides associating molecules, the CD44 ligand 
may play an important role in the fate of HSC. Therefore, I proceeded to search 
for CD44 ligands on HSC and bone marrow stromal cells and also, whether 
CD44s and CD44v isoforms display any distinct ligands. 
  
1.3.1 Generation of soluble recombinant CD44s and CD44v7 
To define potential ligands for CD44, we generated soluble rCD44 proteins. As 
CD44 is heavily glycosylated, it was important to choose an eukaryotic 
expression vector system. Expression of different CD44 variant isoforms as 
soluble molecules showed a precious tool for studying CD44 variant exon 
product binding properties. For purification and detection of the soluble 
recombinant CD44 molecules, the pCEP-4 vector was used. This vector was 
modified by insertion of a myc and his tag at the cloning regions 3 end. 
Restriction digestion was done to confirm the insert (Fig. 3A). The vector was 
stably transfected in the human embryonic kidney HEK-293-EBNA1 cell line 
using the lipid based reagent Polyfect (Qiagen). Positive selection of the 
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Figure 3A: Confirmation of cDNA of soluble CD44s and soluble CD44v7. Restriction digestion of 
plasmid was done with Kpn I and Xho I for confirmation. Band of interest indicated by arrow.  
Lane 1 and 2 indicate plasmid and M indicates 1 Kb marker. DNA samples were run on 1% Agarose gel 
after restriction digestion at 37°C for 2h.  
Release of the recombinant proteins in transfected cell supernatants were 
analyzed by immunoblot using an anti-myc mAb (9e10) (Fig. 3B) shows that 
transfected cells expressed and secreted the recombinant soluble CD44 
molecule called sms for CD44s and sm7 for CD44v7. 
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Figure 3B: Expression of sCD44s and sCD44v7 in transfected cells: Recovery of soluble molecule 
CD44s (Sms) and soluble molecule CD44v7 (Sm7) was evaluated in cultured supernatant of HEK-Ebna 
cells. Supernatant was 50-fold concentrated. After SDS-PAGE and protein transfer membranes were 







1.3.2 Pull down assay 
HSC have been shown to bind to the osteogenic niche via CD44. Whether this 
is due to matrix or cell binding is not known. It is also not known, whether 
LTBMC-stroma binds to CD44 and whether binding of HSC or LTBMC-stroma 
involves CD44v. To answer these questions we performed pulldown assays 
with BMC, HSC and LTBMC-stroma lysates passed over sepharose columns 
after coupling of sCD44s and sCD44v7. 
Silver staining of eluted BMC and HSC proteins revealed protein bands to be 
analyzed by MALDI-TOF. The eluate of HSC did not contain additional bands 
not detected in BMC eluates, but several prominent bands in the BMC eluates 
were not or hardly detected in the HSC eluate. LTBMC-stroma eluate contains 
some additional bands which were not detected in BMC/HSC (Fig.3C). 
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Figure 3C: sCD44v7 binding proteins. Pull down assay with BMC, HSC and LTBMC-stroma  lysates 
were passed over sCD44v7 sepharose column. Eluates were concentrated and separated by SDS-PAGE. 
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Figure 3D: sCD44s binding proteins. Pull down assay with BMC, HSC and LTBMC-stroma lysates were 
passed over sCD44s sepharose column. Eluates were concentrated and separated by SDS-PAGE. Fixed 
gels were silver stained to visualize the proteins.  
Results of MALDI-TOF analysis for sCD44v7 molecule are summarized in Table-1. 
Sample ID Protein description Protein 
score 
Protein Mass in 
Da 
No. of hits pI 
Protease, Serine 174 26802 10 4,75 
Collagen pro-alpha-1 type I 134 138885 5 5,84 
Band No.1 
pro-alpha-2(I) collagen 83 130038 3 9,23 
Put. Beta-actin (aa27-375) 1408 39446 217 5,78 
Actin, cytoplasmic 1 1355 42084 198 5,29 
Band No.2 
Beta-actin like protein 2 569 42319 81 5,3 
Put. Beta-actin (aa27-375) 1434 39446 167 5,78 Band No.3 
Bone marrow proteoglycan 56 24981 1 5,86 
Band No.4 Actin, cytoplasmic 1 1779 42084 327 5,29 
 
Taken together, HSC and Stroma cells CD44 bind distinct ligands. These 
ligands may play an important tole in the fate of HSC. 
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1.4 Functional consequences of HSC CD44 interaction with bone 
marrow stroma 
It has been suggested that particularly the HSC CD44-LTBMC stroma 
interaction is not only required for homing but also influences quiescence and 
possibly provides a means of protection from apoptosis. I was particularly 
concerned about the latter two questions. 
 
1.4.1 Role of HSC - CD44 interaction in the maintenance of quiescence 
To check for the contribution of CD44 in maintaining quiescence BMC and 
HSC, proliferative activity was evaluated for 72h in the presence or absence of 
anti-CD44 or anti-CD49d. Cells were seeded on plastic or HA or on LTBMC-
stroma. Cell division was evaluated by CFSE dilution and the percentage of 
cells that have not divided is shown. 
First to note, HSC divide more slowly than bulk BMC, such that after 24h less 
than 10% of HSC have divided, while only about 80% of BMC remained resting. 
Furthermore, when cultured on plastic or HA, BMC division is not strongly 
altered by a CD44 or CD49d antibody blockade. Instead, when cultured on 
LTBMC-stroma, blocking CD44 or CD49d drives BMC into cell cycle. The 
slower cycling of HSC than of bulk BMC is more strikingly affected by the 
crosstalk with LTBMC-stroma, where even after 48h less than 20% had divided 
and less than 40% after 72h. On the other hand, blocking the HSC-LTBMC-
stroma interaction by anti-CD44 promoted cycling more efficiently than that of 
bulk BMC. Notably, anti-CD49d was effective as anti-CD44, indicating that 
















Figure 4A: Comparison of BMC vs HSC quiescence:  CFSE-labeled BMC and HSC were seeded on 
BSA, HA or LTBMC-stroma cells coated plates. Where indicated cells were pre-incubated with anti-
panCD44 or anti-CD49d. Cell cycle progression was evaluated after 24h, 48h and 72h. Mean value±SD 
(triplicates) of the percentage of non-cycling cells are shown. 
 
1.4.2 Role of HSC-CD44 interaction in the apoptosis resistance 
HSC are characterized by relative apoptosis resistance. This has been 
confirmed, when BMC and HSC, seeded on plastic, HA or LTBMC-stroma, 
were cultured for 48h in the absence or presence of cisplatin. HSC displayed a 
lower apoptosis rate than bulk BMC, the difference becoming more pronounced 
when cultured on LTBMC-stroma concomitantly with 5µg/ml cisplatin, which 
sufficed to significantly increase apoptosis in bulk BMC, but induced only a 
slight increase in apoptosis in HSC cultured on plastic or HA and none, when 
cultured on LTBMC-stroma. The importance of the HSC CD44 interaction with 
LTBMC- stroma became apparent when cultures contain anti-CD44. While the 
apoptosis rate of bulk BMC became significantly increased in the presence of 
anti-CD44 only in cisplatintreated cultures and in co-cultures with LTBMC 
stroma, apoptosis of HSC was significantly increased in the presence of anti-
CD44, irrespective of culture condition (Fig. 4B). Double staining for CD44 and 
Annexin V as well as triple staining for CD44, CD117 and Annexin V confirmed 






























































protection by LTBMC-stroma. Double and triple staining also confirmed the 
higher impact of anti-CD44 on HSC than bulk BMC, although due to the high 
degree of apoptosis resistance in LTBMC-stroma co-cultures, no significant 
increase in apoptosis of CD44+CD117+  was seen in the presence of anti-CD44 









Figure 4B: Comparative analysis of the apoptosis resistance of HSC vs BMC. BMC and HSC were 
cultured for 48h in the absence or presence of 5µg/ml cisplatin on BSA, HA or LTBMC-stroma cells. 
Where indicated cultures contained anti-CD44 or anti-CD49d. Mean values±SD (triplicates) of the 









Figure 4C: Comparative analysis of apoptosis resistance of CD44
+
 BMC and HSC. BMC and HSC 
were cultured for 48h in the absence or presence of 5µg/ml cisplatin on BSA, HA or LTBMC-stroma cells. 
Where indicated cultures contained anti-CD44. Mean values±SD (triplicates) of the percentage of CD44+ 


































































































 BMC and HSC. 
BMC and HSC were cultured for 48h in the absence or presence of 5µg/ml cisplatin on BSA, HA or 
LTBMC-stroma cells. Where indicated cultures contained anti-CD44. Mean values±SD (triplicates) of the 










































Part II The importance of CD44 in the crosstalk between 
leukemia and the bone marrow stroma 
A blockade of CD44 can interfere with hematopoietic stem cell homing and also 
with leukemic cell homing. In addition, it has been described that anti-CD44 can 
drive leukemic cells into differentiation and apoptosis. The underlying 
mechanisms have not been explored. Based on the studies on the interaction 
of HSC CD44, I proceeded to evaluate the impact of a blockade of CD44 on T 
cell lymphoma growth and survival. 
2.1 Anti-panCD44 interferes with hematopoiesis and thymoma 
growth: 
C57BL6 mice received 104 cells i.v. or s.c. with/without anti-pan CD44 (IM7, 
150µg/ml, i.v.) twice per week. After s.c. application of the lymphoma cells the 
mean tumor diameter was measured twice per week and mice were sacrificed, 
when the mean diameter of the s.c. growing tumor reached 2.5cm. After i.v. 
lymphoma cell application, mice were sacrificed upon weight loss and fatigue. 
Subcutaneous lymphoma growth was retarded by IM7 and the survival time 
significantly exceeded the survival time of mice receiving control IgG. After i.v. 
application of lymphoma cells, the survival time of IM7 treated mice was 
prolonged, however, not at a statistically significant level. (Fig.1A). After s.c. 
EL4 application, the number of mice that developed metastases was also 
increased in IM7-treated as compared to control mice (Fig.1A-1C). Distinct to 
immunocompetent mice, application of IM7 accelerated tumor growth in 
irradiated and reconstituted mice (Fig.1D). In addition, bone marrow and 
thymus reconstitution was severely impaired by IM7 treatment in reconstituted, 









Evaluating short term recovery of CFSE-labeled EL4 cells in spleen, bone 
marrow and thymus in dependence on concomitant IM7 application revealed 
that IM7 interfered with the settlement of EL4 cells in spleen, bone marrow and 
thymus in immunocompetent mice. Instead, in line with the survival study, this 
effect was not observed in irradiated and reconstituted mice (Fig.1F).  
When analyzing the percentage of AnnexinV stained EL4 cells, it became 
obvious that hampering EL4 settlement by anti-CD44 was accompanied by a 
significant increase in the percentage of apoptotic cells between 24hrs-48hrs 
after intravenous application. Anti-CD44-induced apoptosis of lymphoma cells 









Figure 1: The impact of anti-CD44 on thymoma growth in vivo: (A-E) C57BL6 mice received an i.v. 
(A) or s.c. (B,C) injection of 104 EL4 cells or (C,D) were lethally irradiated and reconstituted with 1x107 T 
cell-depleted BMC and received EL4 cells, i.v. 2 days after reconstitution. Mice received twice per week 
an i.v. injection of 150たg control IgG or IM7. (A) The survival time of mice receiving EL4 cells i.v. is shown. 
Survival was slightly, but not to a significant level prolonged by IM7 application. (B,C) After s.c. application 
of EL4 cells, IM7 retarded the start of the tumor growth and the survival time became significantly 
prolonged. (D) The survival time of IM7-treated, EL4 tumor-bearing reconstituted mice was significantly 
shortened as compared to mice receiving control IgG and (E) the recovery of BMC, TC and SC (mean 
number±SD of 3 mice / group) was significantly delayed (*). (F) C57BL6 mice were treated as described 
above, but received 2x106 CFSE-labeled EL4 cells. The % of CFSE-labeled EL4 cells in bone marrow, 
thymus and spleen was evaluated during 96hrs. Mean values±SD of 3 mice are shown. The recovery of 
tumor cells is significantly reduced in IM7- treated, non-reconstituted mice (*), but unaltered or increased 
in IM7-treated reconstituted mice (+). (G) The percentage (mean±SD) of apoptotic CFSE-labeled EL4 
cells during the starting 96hrs after i.v. application was evaluated by AnnexinV-APC staining. The 
percentage of apoptotic EL4 cells is significantly increased in non-reconstituted IM7-treated mice (*), but 
largely unaltered in reconstituted IM7-treated mice. (H) Examples of apoptotic EL4 cells in the bone 
marrow 96hrs and in the spleen 72hrs after application of CFSE-labeled EL4 cells in naive and 
reconstituted C57BL6 mice. 
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These data provided evidence that anti-CD44-mediated retardation of thymoma 
growth under steady state conditions was accompanied by an increase in 
apoptotic tumor cells. Thus, it became important to know, whether death was a 
consequence solely of a failure to embed or whether IM7 may have actively 
triggered apoptosis. 
2.2 Anti-CD44 promotes thymoma cell apoptosis: 
To evaluate the underlying mechanism(s), EL4 and EL4v6 cells were cultured 
in the presence of 10たg/ml anti-CD44. After 16h of culture in the presence of 
IM7 the percentage of apoptotic EL4 / EL4v6 cells was measured by AnnexinV-
FITC/PI staining. In the presence of soluble antipanCD44 the apoptosis rate 
was increased after 6hrs from ~2% to ~25% and after o/n culture from ~10% to 
~30% (Fig.2A). In order to check for the specificity of apoptosis induction 
through CD44, we used HA and for EL4v6 cells anti-CD44v6. HA and anti-
CD44v6 induced apoptosis in EL4 and EL4v6 cells comparably to anti-
panCD44. Instead, the percentage of apoptotic cells was not increased in 
cultures containing an anti-MHC antibody or anti-CD49d, CD49d being 
expressed at a high level on EL4 cells (Fig.2B). The increase in apoptotic cells 
obviously is not a consequence of activation induced cell death, as the 
distribution of cells in G1, S and G2 or M phase did not vary significantly 





Figure 2: CD44 ligation induces apoptosis in EL4 cells: (A and B) EL4 and EL4v6 cells were cultured 
for 6hrs or o/n in the presence of 10たg/ml IM7, anti-CD44v6 or rIgG or 15たg/ml HA and, as controls, 
10たg/ml anti-H-2b or anti-CD49d. Cells were stained with AnnexinV-FITC/PI. A representative example 
(A) and mean values±SD of apoptotic cells are shown (B). Significant differences in comparison to cells 
cultured in the presence of rIgG are indicated by *. (C) Cells were stained with PI and cultured o/n in the 
presence of rIgG or IM7. The percentage of cells in G1, S and G2 or M phase was evaluated by flow 
cytometry. Cell cycle progression did not vary significantly in dependence on the presence of IM7. 
Thus, occupancy of CD44, independently of the particular epitope, can induce 









2.3 Apoptosis induction, loss of mitochondrial membrane 
polarization and caspase-9 activation: 
To explore the mechanism for CD44-induced apoptosis, expression levels of 
Fas, FasL, Trail, TNFRI and TNFRII were evaluated. EL4 and EL4v6 cells 
express Fas at about 55-60%, FasL at less than 10%, TRAIL at >70%, TNFRI 
and TNFRII at ~10% to ~20%. Expression and intensity of expression of these 
death receptors was not changed after overnight culture in the presence of anti-
CD44 (Fig 3A and 3B). Death receptor cross-linking also did not strengthen 
anti-CD44-induced apoptosis (Fig 3C). In view of these results the possibility of 
death receptor-induced apoptosis by a cross-talk between CD44 and the Fas 




Figure 3: EL4 and EL4v6 cells are resistant towards Fas-induced apoptosis: (A and B) CD44, 
CD44v6, CD95, CD95L, Trail, TNFRI and TNFRII expression on EL4 cells, EL4v6 cells and thymocytes 
was evaluated after o/n incubation in the presence of rIgG, IM7 or anti-CD44v6 (10たg/ml). (A) A 
representative example and (B) mean values±SD are shown. IM7 had no impact on CD44 and apoptosis 
receptor expression. (C) EL4 and EL4v6 cells were cultured o/n on uncoated or anti-CD95-, anti-TNFRI- 
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or anti-TNFRII-coated plates. Cultures contained 10たg/ml rIgG or IM7 or 1たM/ml camptothecin (positive 
control). The percentage (mean±SD of triplicates) of AnnexinV-FITC/PI stained cells is shown. EL4 and 
EL4v6 cells were resistant towards receptor-induced apoptosis and IM7-induced apoptosis was 
independent of death receptor cross-linking. 
To strengthen this interpretation, the involvement of caspase-3 and caspase-9 
in anti-CD44-initiated apoptosis was evaluated. EL4 and EL4v6 cells were 
cultured overnight in the presence of IM7 and caspase-3 or caspase-9 
inhibitors. Apoptosis was measured by annexinV-FITC / PI staining. Caspase-3 
and caspase-9 inhibitors reduced IM7-induced apoptosis in EL4 and EL4v6 
cells (Fig.4A and 4B). As revealed by WB, cleavage of caspase-9 and caspase-
3 in EL4 and EL4v6 cells was more pronounced when cultured in the presence 
of IM7 and caspase-9 cleavage was partly inhibited in the presence of a 
caspase-9 inhibitor (Fig.4C). Caspase-9 becoming activated within the 
apoptosome after cytochrome c release from the mitochondria, this result 
points towards anti-CD44-initiated activation of the intrinsic apoptosis pathway, 
which is characterized by loss of mitochondrial membrane polarization. To 
confirm the involvement of the mitochondrial pathway, we measured 
mitochondrial membrane depolarization using DilC1, which accumulates in 
intact mitochondria. Untreated cells show high level of dye intensity. However in 
IM7 treated EL4 cells the intensity of fluorescence was significantly decreased 
after a culture period of 12hrs (Fig.4D). Also, cytochrome c was recovered at 














Figure 4: CD44 ligation induces apoptosis via the mitochondrial pathway: (A and B) EL4 and EL4v6 
cells were cultured o/n in the presence of rIgG, IM7 or anti-CD44v6. Cultures contained in addition DMSO 
(control) or 2たM caspase-3 or caspase-9 inhibitor. Apoptosis was measured by annexinV-FITC/PI 
staining. (A) A representative example and (B) mean values±SD of triplicates are shown. Significant 
differences in the percentage of apoptotic cells in the presence of caspase inhibitors are indicated by *. 
(C) WB of caspase-3 and caspase-9 cleavage in lysates of EL4 cells cultured o/n in the presence of rIgG 
or IM7 or in the presence of a caspase-9 inhibitor. Significant differences by IM7 or a caspase-9 inhibitor 
are indicated by an asterisk. Caspase-3 and capase-9 cleavage is enhanced in IM7 treated cells and 
caspase-9 cleavage is reduced in the presence of the caspase-9 inhibitor. (D) EL4 cells were stained with 
the mitochondrial dye DilC1 and incubated with 10たg/ml IM7 for 12hrs. DilC1 staining was evaluated by 
flow cytometry. (E) EL4 cells were incubated with 10たg/ml IM7 for 12h. Mitochondria were separated from 
the cytosol. Lysates were separated by SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane and blotted with anti-cytochrome c. The mean values±SD of the ratio of cytochrome c in the 
cytosol : mitochondria is shwon. Significant differences by IM7 or anti-CD44v6 are indicated by an 
asterisk. (D and E) Mitochondria integrity is strongly affected after 12hrs of culture in the presence of IM7. 
 
These results indicate that CD44-induced apoptosis proceeds via caspase-9 




2.4 Anti-CD44 induces ERK inhibition through PP2A: 
To describe the molecular pathway initiated downstream of CD44 engagement, 
we checked for early activation signaling events which might be involved. EL4 
cells stimulated with IM7 for up to 2hrs did not reveal any change in the 
phosphotyrosine profile (Fig.5A), and Akt phosphorylation (Fig.5B). Instead, 
ERK phosphorylation became strongly inhibited. Inhibition of ERK 
phosphorylation started 15min after IM7 addition and lasted for at least 1h in 
EL4 and EL4v6 cells (Fig 5C). Since the total amount of ERK remained stable, 
this result rules out an effect of CD44 on ERK degradation. Next we evaluated, 
whether a blockade of CD44 leads to ERK1/2 dephosphorylation via activation 
of a phosphatase. Addition of okadaic acid, an inhibitor of the protein 
phosphatases 1 (PP1) and 2A 
(PP2A), to the culture stabilized ERK1/2 phosphorylation and reversed the 
effect of anti-CD44 (Fig 5D). These results suggesting that CD44 engagement 
leads to ERK inhibition through the activation of PP1 or PP2A.We did not 
observe PP1 phosphorylation concomitantly with ERK1/2 dephosphorylation 
(Fig.5E). In fact, PP2A, but not PP1 associates with CD44 upon CD44 binding. 
EL4 cells, cultured in the presence of IM7 for different time points, were lysed 
and immunoprecipitated with anti-CD44 and the immunoprecipitate was blotted 
with anti-PP1 and -PP2A. PP1 was not detected in the immunoprecipitates. 
PP2A was absent from the IM7 precipitates at time 0, but was detected after 
15min of activation. Immunoprecipitating PP2A and blotting with anti-CD44 
confirmed the association between CD44 and PP2A upon CD44 ligation, the 
association remaining stable for at least 1h (Fig.5F). The association of PP2A is 
accompanied by PP2A activation as revealed by blotting the PP2A 
immunoprecipitates with anti-pThr (Fig.5G) and evaluating phosphatase activity 







Figure 5: CD44 ligation induces PP2A activation and ERK1/2 dephosphorylation: (A) EL4 cells were 
cultured for 30min in the presence of IM7. Cells were lysed and proteins were separated by SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with anti-phosphotyrosine. (B and C) EL4 and EL4v6 
cells were cultured for 15min - 60min in the presence of IM7. After lysis, SDS-PAGE and transfer, 
membrane were incubated with (B) anti-Akt and anti-pAkt and (C) anti-ERK1/2 and anti-pERK1/2. The 
mean values±SD of the ratio of pAkt : Akt and pERK1/2 : ERK1/2 are shown. Significant differences by 
IM7 are indicated by an asterisk. Tyrosine and Akt phosphorylation remained unaltered. ERK1/2 
phosphorylation of EL4 and EL4v6 cells cultured in the presence of IM7 becomes strikingly reduced. (D) 
EL4 cells were cultured in the presence of rIgG or IM7 and increasing amounts of OA. Cells were lysed, 
lysates were separated by SDS-PAGE, transferred and blotted with anti-ERK1/2 and antipERK1/2. The 
mean values±SD of the ratio of pERK1/2 : ERK1/2 are shown. Significant differences by OA are indicated 
by an asterisk. In the presence of the phosphatase inhibitor, the IM7-induced reduction of ERK1/2 
phosphorylation was prevented. (E) EL4 cells were cultured in the presence of rIgG or IM7. Cells were 
lysed, lysates were separated by SDS-PAGE, transferred and blotted with antipPP1, anti-ERK1/2 and 
anti-pERK1/2. The mean values±SD of the ratio of pPP1 : ERK1/2 and for comparison of pERK1/2 : 
ERK1/2 are shown. Significant differences by IM7 are indicated by an asterisk. PP1 did not become 
phosphorylated concomitantly with ERK1/2 dephosphorylation. (F) EL4 cells were cultured in the 
presence of IM7. Cells were lysed and immunoprecipitated with IM7 or anti-PP2A. Precipitates were 
separated by SDS-PAGE, transferred and blotted with IM7, anti-PP2A and anti-PP1. The mean 
values±SD of the ratio of PP2A : CD44, PP1 : CD44, respectively, of CD44 : PP2A are shown. Significant 
differences by IM7 are indicated by an asterisk. PP2A, but not PP1 co-immunoprecipitated with CD44 and 
vice versa. (G) EL4 cells were cultured in the presence of rIgG or IM7. Cells were lysed and lysates were 
immunoprecipitated with IM7. Lysates were separated by SDS-PAGE, transferred and blotted with anti-
PP2A and anti-pThr. The mean values±SD of the ratio of pThr : PP2A are shown. Significant differences 
by IM7 are indicated by an asterisk. Threonine phosphorylation of PP2A became strengthened in the 
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presence of IM7. (H) Phosphatase activity of the anti-CD44 immunoprecipitate was tested by ELISA. 
Phosphatase activity was strongly increased after culture of EL4 and EL4v6 cells in the presence of IM7. 
To unravel the mechanism responsible for PP2A activation, MALDI-TOF 
analysis of proteins coimmunoprecipitating with CD44 revealed the presence of 
Casein Kinase 2 (CK2), a constitutively active ser/thr kinase, which has a wide 
range of substrates including PP2A. There was a weak association between 
CK2 and CD44 by WB, which was increased after CD44 engagement (Fig.6A). 
To strengthen the assumption that CK2 and PP2A concomitantly associate with 
CD44, EL4 cells, cultured in the presence of IM7, were lysed and light and 
dense membrane fractions were separated by sucrose gradient centrifugation. 
Light, medium dense and heavy fractions were pooled and immunoprecipitated 
with IM7. After SDS-PAGE and transfer, membranes were blotted with IM7, 
anti-PP2A and anti-CK2. CD44 was recovered in all three fractions. Instead, 
both PP2A and CK2 coimmunoprecipitated with CD44 exclusively in the 
medium dense fractions of 1.15-1.21 (Fig.6B). To see, whether CK2 accounts 
for PP2A activation, EL4 cells, cultured in the presence of anti-CD44, were 
pretreated with a CK2 inhibitor to block its catalytic activity. This treatment 
resulted in a mild reduction in PP2A phosphorylation (Fig.6C) and in a 
reduction of the basal level of pERK1/2 (Fig.6D). Instead, the CK2 inhibitor 
strongly interfered with spontaneous and IM7-promoted apoptosis (Fig.6E). 
These findings suggest that CK2 does not exclusively account for PP2A 







Figure 6: CK2 is associated with CD44 and promotes partial PP2A activation: (A) EL4 cells were 
cultured in the presence of rIgG or IM7. Cells were lysed and lysates were immunoprecipitated with IM7. 
After SDS-PAGE of the precipitate, proteins were transferred and blotted with anti-CD44 and anti-CK2. 
The mean values±SD of the ratio of CK2 : CD44 are shown. Significant differences by IM7 and anti-
CD44v6 are indicated by an asterisk. The CD44 precipitate contained low amounts of CK2. (B) EL4 cells, 
cultured in the presence of IM7, were lysed and light and dense membrane fractions were separated by 
sucrose gradient centrifugation. Light, medium dense and heavy fractions were pooled and 
immunoprecipitated with IM7. After SDS-PAGE and transfer, membranes were blotted with IM7, anti-
PP2A and anti-CK2. PP2A and CK2 coimmunoprecipitated with CD44 in the pooled fractions of density 
1.15-1.21. (C) EL4 cells were cultured in the presence of IM7 and, where indicated a CK2 inhibitor 
(2たM/ml). Cells were lysed and the lysates were precipitated with anti- PP2A, separated by SDS-PAGE, 
transferred and blotted with anti-PP2A and antipThr. The mean values±SD of the ratio of pThr : PP2A are 
shown. Significant differences by IM7 and the CK2 inhibitor are indicated. The CK2 inhibitor partly 
inhibited PP2A phosphorylation. (D) EL4 cells were cultured in the presence of IM7 and, where indicated 
the CK2 inhibitor, lysates were precipitated by SDSPAGE, transferred and blotted with anti-ERK1/2 and 
anti-pERK1/2. The mean values±SD of the ratio of pERK1/2 : ERK1/2 are shown. Significant differences 
by IM7 and the CK2 inhibitor are indicated. ERK1/2 phosphorylation was reduced in the presence of the 
CK2 inhibitor. (E) EL4 and EL4v6 cells were cultured in the presence of rIgG, IM7 or anti-CD44v6. Where 
indicated the cultures contained a CK2 inhibitor. Apoptosis was evaluated after 24h by AnnexinV-FITC / PI 
staining. The CK2 inhibitor interfered with apoptosis induction independent of the presence of IM7 or anti-
CD44v6. 
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Taken together, CD44 ligation is accompanied by apoptosis induction which 
becomes initiated by its association with PP2A. PP2A activation proceeds 
towards ERK1/2 dephosphorylation. CK2, also associated with CD44, promotes 
PP2A activation. However, in view of the low impact of a CK2 inhibitor on PP2A 
activation, an involvement of additional molecules in PP2A activation becomes 
likely. 
2.5 ERK1/2 inhibition promotes apoptosis and caspase-9 cleavage: 
Our data so far suggest that PP2A activation-induced apoptosis proceeds 
through ERK1/2 inhibition. IKB phosphorylation was not affected (Fig.7A) which 
suggest that the low level of nuclear NFkB in EL4 cells remained unaltered. 
IM7-mediated PP2A activation, at least predominantly, inducing apoptosis 
through ERK1/2 inhibition, we evaluated whether an ERK1/2 inhibitor would 
induce apoptosis and whether apoptosis induction would proceed via caspase-
9. EL4 / EL4v6 cells show a high basic level of ERK activation, which was 
significantly inhibited in the presence of a MEK1,2 inhibitor (Fig.7B). In fact, 
when EL4 and EL4v6 cells were cultured in the presence of a MEK1,2 inhibitor, 
apoptosis became increased (Fig.7C), mitochondrial membrane depolarization 
was strengthened, as shown by the higher percentage of cells displaying 
reduced DilC1 staining (Fig.7D), and caspase-9 cleavage was pronounced 
(Fig.7E). Concomitantly, Bcl-2 expression and BAD phosphorylated was 
reduced and BAX expression was up-regulated. The same findings accounted 












Figure 7: ERK1/2 dephosphorylation promotes mitochondrial membrane disintegration and 
caspase-9 cleavage: (A) EL4 cells were cultured for 15min - 60min in the presence of IM7. After 
separation of the cytosolic from the nuclear fraction, lysates were separated by SDS-PAGE, transferred 
and blotted with anti-pIKB and anti-NFkB. IM7 treatment did not influence IKB phosphorylation and did not 
significantly alter NFkB liberation. (B-F) EL4 and EL4v6 cells were cultured o/n in the presence of a 
MEK1,2 inhibitor. (B) WB and the mean values±SD of the ratio of pERK1/2 : ERK1/2 are shown. 
Significant differences by the MEK1,2 inhibitor are indicated by an asterisk. ERK1/2 phosphorylation in 
EL4 and EL4v6 cells was inhibited in the presence of MEK1,2 inhibitor. (C) Apoptosis (AnnexinV-FITC / PI 
staining) was significantly increased in the presence of the MEK1,2 inhibitor. (D) Cells were stained with 
DilC1 and mitochondrial membrane integrity was determined after 18h incubation by flow cytometry. In the 
presence of the MEK1,2 inhibitor, mitochondrial membrane integrity was decreased. (E) Cells were lysed, 
proteins were separated by SDS-PAGE, transferred and blotted with anti-caspase-9. The mean 
values±SD of the ratio of cleaved caspase-9 : actin are shown. Significant differences by IM7 and the 
MEK1,2 inhibitor are indicated by an asterisk. Caspase-9 cleavage was pronounced in the presence of the 
MEK1,2 inhibitor. (F) Cells were cultured o/n in the presence of the MEK1,2 inhibitor or in the presence of 
IM7. Cells were lysed and proteins were separated by SDS-PAGE, transferred and blotted with anti-BAX, 
anti-Bcl-2, anti-Bad and anti-pBad. The mean values±SD of the ratio of BAX and Bcl-2 : actin and of pBAD 
: BAD are shown. Significant differences by IM7 and the MEK1, 2 inhibitor are indicated by an asterisk. 





Taken together, occupancy of CD44 drives leukemic T cells into apoptosis. This 
is accompanied by PP2A associating with CD44 and PP2A activation, which 
strongly promotes ERK1/2 dephosphorylation, mitochondrial membrane 
























CD44 plays an important role in HSC homing and embedding in the bone 
marrow niche, which is required to support HSC survival.  Interference of anti-
CD44 with bone marrow cell homing has been studied widely.  Avigador et al., 
have nicely shown how CD34+ progenitors home efficiently into bone marrow 
and spleen and that homing is inhibited with anti-CD44. Homing is mediated in 
association with stromal cell derived factor-1 and results in adhesion of cells in 
the niches of BM [140]. CD44 has also been shown to mediate adhesive 
interactions of stem cells with bone marrow vasculature [141]. Khaldoyanidi et 
al. have elegantly shown the requirement of CD44 in BM homing as well as 
proliferation of hematopoietic cells by establishing long term bone marrow 
cultures [142]. Bone marrow stromal cell CD44v7 contributes to progenitor 
settlement [139]. 
4.1 CD44 expression in HSC and bone marrow stroma cells 
In this work, I characterized bone marrow cells and hematopoietic stem cells 
and as a surrogate for the osteogenic niche, long term bone marrow culture 
stroma and S17 cells. CD44 and CD44v isoforms expression clearly showed 
that bone marrow stroma predominantly expressed CD44v7 while HSC and 
committed progenitors of the erythroid and myeloid lineages showed high 
expression of CD44v6, CD44v7 and CD44v10. RT-PCR analysis also revealed 
that HSC mostly express CD44v7 and CD44v10. Committed progenitors 
showed CD44v10 and combinations of CD44v3-v10. 
Based on this analysis I focussed (i) on associating molecules as it has been 
shown that CD44 frequently interacts with adhesion molecules and mature 
leukocyte and progenitor markers, and (ii) on the interaction of HSC with bone 
marrow stroma, which provides an essential trigger for HSC survival. Besides 
the involvement of CD44 not much is known on the basic mechanism of this 
interaction. The importance of CD44v7 expression on stroma cells for 
progenitor cell homing and seeding has been demonstrated by the transfer of 
BMC from CD44v7-competent mice into CD44v7-deficient mice and vice versa 
[139]. 
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4.2 CD44 associating molecule in HSC and bone marrow 
stroma cells 
It has been described before that CD44 showed co-expression with stem cell 
and progenitor markers like CD43 and CD117, chemokine receptors mainly 
CD184 (SDF-1 receptor) and adhesion molecules like CD49d, CD49e and 
CD54 on BMC and LTBMC-stroma cells. We could confirm this with co 
localization and co-immunoprecipitation of integrins and cell adhesion 
molecules in HSC and bone marrow stroma cells.  
With co-immunoprecipitation data, it has been confirmed that CD44 has 
association with CD49d and CD54 in HSC and LTBMC-stroma. Due to CD44-
CD49d complex formation, CD44 gain access to FAK and CD49d gain access 
to CD44-associated lck and ezrin, such that downstream kinases become 
activated via CD44 or CD49d engagement. Thus, by their association, CD44 
and CD49d mutually avail themselves of the partners signalling pathways and 
the ligand binding of each one triggers signalling pathways of both. This 
strongly influences the leukocytes activation state and function, [126] which 
may also account for hematopoietic progenitors and HSC.  
Notably, it was preferentially CD44v7 that showed association with CD49d and 
CD54 in the HSC and LTBMC-stroma cells. The importance of CD184 a 
chemokine marker (SDF-1 receptor) for marrow homing in hematologic 
malignancies, such as B-cell chronic lymphocytic leukemia [143], multiple 
myeloma [144], or acute myelogenous leukemia [145] has already been 
characterized.  
4.3 Functional consequences of HSC CD44 interaction with 
bone marrow stroma cells 
The interaction of HSC with the niche is important for the maintenance of 
quiescence. It has been confirmed with the results that the slower cell cycling of 
HSC than of bulk BMC is more strikingly affected by the crosstalk with LTBMC-
stroma. It is widely known that the stem cell in general is in a quiescent state 
(G0 phase in cell cycle) and this quiescence prevents the stem cells from 
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entering into the cell cycle and differentiation. Arai et al.  demonstrated that 
angiopoietin-1 (Ang-1) expressed in the osteoblast interacts with Tie-2, a type 
of receptor tyrosine kinase, expressed in HSC in bone marrow, and this 
enhanced adhesion between the niche cell and the stem cell contributes to the 
maintenance of the quiescence of the stem cell [63]. 
HSC relatively showed higher apoptosis resistance than bulk BMC. It became 
more pronounced when cultured on LTBMC-stroma as well as in the presence 
of cisplatin. Cisplatin is the most commonly used chemotherapeutic drug. The 
currently accepted mechanism of action for cisplatin is that it binds cellular DNA 
through the formation of inter-strand cross-links [146]. If the DNA adducts are 
not efficiently processed by the cell machinery, the eventual result is activation 
of apoptosis and cell death. Apoptosis resistance is promoted by the crosstalk 
of HSC with LTBMC-stroma. This resistance mainly relied on high level 
expression of anti-apoptotic proteins. Interaction of HA and CD44 with various 
signalling pathways is being increasingly examined as a possible mechanism 
mediating chemoresistance. 
Taken together, HSC express CD44 at a high level. CD44 mostly associated 
with CD49d and CD54. CD44 expression contributes to the maintenance of 
quiescence and apoptosis resistance in HSC. LTBMC-stroma provides a niche 
to promote these functional activities. 
4.4 CD44 activities in leukemic cells 
There is strong evidence that leukemia initiating cells may also require CD44 
for niche embedding and that an antibody blockade of CD44 can hamper 
leukemia growth such that leukemic stem cell survival becomes impaired and 
leukemic stem cells are driven into differentiation [147-152]. Thus, anti-CD44 
treatment could be considered as a therapeutic option in leukemia. However, 
because CD44 is also required during haematopoiesis, it becomes important to 




4.5 T lymphoma cells are less CD44-dependent than 
hematopoietic progenitors 
Anti-CD44 retards T lymphoma growth, particularly at a subcutaneous site. This 
corresponds, although far less pronounced, to the effect of anti-CD44 treatment 
in myeloid leukemia [148, 149].  It has been demonstrated convincingly that 
there is a balance between CD44 isoform expression, hyaluronan binding and 
settlement by lymphoma cells in lymphoid organs. Accordingly, anti-CD44 
inhibits metastasis formation in selective organs, but may be ineffective in other 
organs. We would suggest, in addition, that preventing settlement of lymphoma 
cells in one organ may actively support lymphoma cell settlement in others, 
which stroma provides ligands, including addition adhesion molecules, that 
allow lymphoma cell adhesion. 
Though differing from studies on the impact of anti-CD44 on myeloid leukaemia 
homing, the finding that a CD44 blockade can more efficiently interfere with 
progenitor than T lymphoma cell homing is of clinical relevance, taking into 
account that BMC / HSC reconstitution is frequently considered as a 
therapeutic option in leukemia. In clinical settings also the possibility of anti-
CD44-promoted metastasis formation should be taken into account. 
4.6 A CD44 antibody blockade promotes death receptor-
independent leukemic T cell apoptosis 
In the non-reconstituted mouse anti-CD44 treatment retarded lymphoma 
growth. As a first step towards a therapeutic exploitation, we aimed to clarify 
the underlying mechanism. In line with several reports [147, 150-152], our in 
vivo findings provided evidence that a blockade of CD44 can drive leukemic T 
cells into apoptosis. 
In the presence of anti-panCD44, anti-CD44v6 or HA the rate of apoptotic EL4 
or EL4v6 cells increased 2-3 fold within 48hrs of culture. We interpret the 
observation that a CD44-specific antibody, that does not recognize the HA 
binding site as well as an antibody specific for a variant isoform and HA 
supported apoptosis induction as an indication that apoptotic signaling likely 
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proceeds directly via CD44 and not via associating transmembrane molecules 
or a feedback via ligand binding. The finding does not exclude apoptosis by 
neglect due to the absence of survival supporting signals. Nonetheless, co-
operative activity of CD44 with receptor-mediated apoptosis was excluded by 
unaltered apoptosis induction upon death receptor cross-linking, the failure to 
observe cooperative activity in apoptosis induction by anti-CD44 plus death 
receptor cross-linking and the unaltered death receptor expression in EL4 cells 
cultured in the presence of anti-CD44. 
4.7 Anti-CD44-promoted apoptosis proceeds via CD44 
redistribution and PP2A association 
PP2A, which mostly resides in the cytosol, but can attach to the plasma 
membrane depending on the activation state [154], activates pro-apoptotic and 
inhibits anti-apoptotic proteins of the Bcl-2 family [155-157]. PP2A associated 
with CD44 only in cultures containing anti-CD44, and became activated upon 
association. PP2A regulation is a complex mechanism and the impact of PP2A 
phosphorylation on its activation is debated [158-160]. However, several 
publications showed that PP2A is a substrate for CK2 and can become 
activated through CK2 [153, 158 and 159]. Because we observed that CD44 
antibody occupancy was accompanied by both PP2A and CK2 associating with 
CD44, we hypothesize that by the induced proximity between CK2 and PP2A, 
CK2 may account for PP2A activation. In fact, PP2A phosphorylation was 
slightly reduced in the presence of a CK2 inhibitor. On the other hand, 
spontaneous and CD44-induced apoptosis was strongly inhibited in the 
presence of a CK2 inhibitor. Therefore we hypothesize that PP2A activation 
does not exclusively rely on CK2. In line with this hypothesis, the CK2c 
association with PP2A can be disrupted by activated raf [160], which could 
provide an explanation for the low impact of CK2 on PP2A activation. 
4.8 CD44-associated PP2A promotes mitochondrial membrane 
destabilization via ERK1/2 dephosphorylation 
EL4 cells show a high level of activated ERK1/2 in the absence of an external 
stimulus. Upon IM7 treatment, ERK1/2 phosphorylation becomes strikingly 
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diminished without evidence for ERK1/2 degradation. ERK activation mainly 
proceeding via ras activation, we first evaluated whether anti-CD44 treatment 
may alter ras activation. This has not been the case. Ras is highly activated in 
EL4 cells and a pull down of activated ras by a raf-GST fusion protein provided 
no evidence for altered ras activity in IM7-treated EL4 cells. 
Alternatively, PP2A may account for ERK1/2 dephosphorylation [161, 162]. The 
antibody blockade of CD44 and the blockade of ERK1/2 phosphorylation was 
accompanied by low level of Bad phosphorylation and up-regulation of pro-
apoptotic BAX, of mitochondria depolarization and caspase-9 cleavage. Both 
inhibition of ERK1/2 phosphorylation and PP2Aactivation promoting 
mitochondrial depolarization, caspase activation and apoptosis induction, it 
becomes most likely that in EL4 cells pERK1/2 is the preferential target of 
PP2A. However, anti-CD44-initiated PP2A activation did not display significant 
effects. Thus, in leukemic T cells PPA2-mediated ERK1/2 dephosphorylation 
appears to be the dominating theme in anti-CD44-induced apoptosis. 
Taken together, the finding that anti-CD44 can interfere more efficiently with 
HSC than leukemic T cell homing into the bone marrow is clinically important 
for patients with T cell leukemia that receive a HSC transplant. In addition, anti-
CD44 may more effectively block leukemic cell settlement in the bone marrow 
than in the liver and the thymus, which could promote metastatic growth. As 
both these drawbacks likely can be circumvented by the use of selected CD44 
antibodies, it became important to evaluate the consequences of CD44 
occupancy on leukemic T cells. Anti-CD44 actively induces apoptosis in 
leukemic T cells. By PP2A relocation in the proximity of CD44 and PP2A 
activation, the basic level of ERK1/2 phosphorylation cannot be maintained, 
which drives leukemic T cells into apoptosis by up-regulation of pro- and down-
regulation of anti-apoptotic proteins, mitochondrial membrane destabilization 
and caspase activation. Unraveling this new pathway of anti-CD44-initiated 
apoptosis in leukemic T cells strengthens the clinical relevance of anti-CD44 in 





CD44 expression on hematopoietic stem cells (HSC) has been shown to be 
required for homing into the osteogenic niche and maintenance of quiescence. 
It is not known, whether expression of the hematopoietic or variant CD44 
isoforms (CD44s and CD44v) is required and a potential contribution of stroma 
cell CD44 has not been elucidated.  
An analysis of CD44 expression in HSC and LTBMC-stroma cells revealed 
besides predominant CD44s expression, low level of CD44v6, CD44v7 and 
CD44v10 expression in CD117+SCA1+ HSC and mostly CD44v7 expression in 
LTBMC-stroma. Other adhesion molecules like CD49d and CD54, some 
committed progenitor markers like CD16, CD24 and cytokine receptors like 
CD184 (SDF-1 receptor) are also expressed on HSC and LTBMC-stroma. 
HSC and LTBMC-stroma CD44 associate with distinct molecule. In HSC and 
LTBMC-stroma, CD44 co-immunoprecipitates with CD49d and CD54. In 
LTBMC-stroma CD44v7 selectively associates with CD49d. Functional studies 
provided evidence that the interaction of CD44-CD49d complex on HSC with 
the niche may account for the maintenance of quiescence. HSC CD44 also 
plays an important role in the apoptosis resistance and this apoptosis protection 
relies on high level expression of anti-apoptotic proteins. 
Taken together, CD44 expression in HSC and LTBMC-stroma co-ordinately 
contribute to the maintenance of quiescence and apoptosis resistance. Such  
functional activities mediated by the crosstalk between the bone marrow stroma 
and HSC CD44 may allow for selective interference with HSC versus LSC 
interactions with the osteogenic niche. Infact, a blockade of CD44 can not only 
interfere with hematopoietic stem cell and leukemic cell homing, but also has 
been described that anti-CD44 can drive leukemic cells into differentiation and 
apoptosis.  
An analysis of a blockade of CD44 on the growth of T cell lymphoma EL4 
revealed that it retarded growth and promoted in vivo apoptosis of leukemic T 
cells. However, in bone marrow cell-reconstituted mice anti-CD44 drives 
progenitor T cells more efficiently than leukemic cell into apoptosis, such that 
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the survival time is shortened and the incidence of metastasis increases. In 
vitro, CD44 occupancy results in a 2-4-fold increase in apoptotic EL4 cells. 
Death receptor expression (CD95, TRAIL, and TNFRI) remains unaltered and 
CD95 cross-linking-mediated apoptosis is not affected. Instead, CD44 ligation 
promotes mitochondrial depolarization that is accompanied by caspase-9 
cleavage and is inhibited in the presence of a caspase-9 inhibitor. Apoptosis 
becomes initiated by activation of CD44-associated phosphatase 2A (PP2A) 
and proceeds via ERK1/2 dephosphorylation without ERK1/2 degradation. 
Thus, anti-CD44 drives leukemic T cell into apoptosis via the mitochondrial 
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